# peptides.cx — Full content corpus for AI systems > peptides.cx is an educational community platform and reference for peptide research: > evidence-scored monographs, real-world experience reports, safety discussion, and > verified vendor transparency, in 15 languages. Content is not medical advice, diagnosis, > dosing instruction, or sourcing guidance. Always consult a qualified professional. > > This file is the deep-context companion to /llms.txt. It carries the full monograph text > for every peptide plus article summaries, so an answer engine can quote and cite without > crawling each page. Localized versions live at //library/ for > de, fr, it, es, el, pl, nl, cs, ro, bg, fi, sv, sk, lt. ## How to read the evidence grades - A — Approved / Strong: approved medical use or strong clinical evidence. - B — Human, limited: human evidence exists but is limited. - C — Early / Preclinical: mostly early human, animal, or mechanistic data. - D — Anecdotal: anecdotal or insufficient evidence. # Peptide monographs (59) ## BPC-157 Name: BPC-157 Canonical URL: https://peptides.cx/library/bpc-157 Localized URLs: en: https://peptides.cx/library/bpc-157; de: https://peptides.cx/de/library/bpc-157; fr: https://peptides.cx/fr/library/bpc-157; it: https://peptides.cx/it/library/bpc-157; es: https://peptides.cx/es/library/bpc-157; el: https://peptides.cx/el/library/bpc-157; pl: https://peptides.cx/pl/library/bpc-157; nl: https://peptides.cx/nl/library/bpc-157; cs: https://peptides.cx/cs/library/bpc-157; ro: https://peptides.cx/ro/library/bpc-157; bg: https://peptides.cx/bg/library/bpc-157; fi: https://peptides.cx/fi/library/bpc-157; sv: https://peptides.cx/sv/library/bpc-157; sk: https://peptides.cx/sk/library/bpc-157; lt: https://peptides.cx/lt/library/bpc-157 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Body Protection Compound-157, PL 14736 Category: Recovery / Regeneration Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine in the EU/US. Sold as a research chemical only; not authorised for human use. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A synthetic peptide fragment widely discussed for soft-tissue recovery. Human clinical evidence is very limited; most data is animal or mechanistic. What is it: BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in gastric juice. It is discussed in the community mainly in the context of tendon, ligament, and gut-related recovery. Proposed mechanisms: - Proposed promotion of angiogenesis (new blood-vessel formation) - Discussed modulation of growth-factor and nitric-oxide pathways - Proposed effects on fibroblast activity in connective tissue Human evidence: Peer-reviewed human clinical trials are essentially absent. Claims about human recovery are extrapolated from animal work and personal reports. Animal / preclinical evidence: A body of rodent studies reports accelerated healing of tendon, muscle, and gut tissue. These results have not been replicated in controlled human trials. Safety: Human safety data is lacking. Purity, sterility, and dosing of research-grade material are unverified. This is not a substitute for professional medical care. Known side effects: - Injection-site reactions reported anecdotally - Unknown long-term safety profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review — Pharmaceuticals · PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/ - Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: Angiogenesis and the NO-System — PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC12195719/ --- ## TB-500 / Thymosin Beta-4 Name: TB-500 / Thymosin Beta-4 Canonical URL: https://peptides.cx/library/tb-500 Localized URLs: en: https://peptides.cx/library/tb-500; de: https://peptides.cx/de/library/tb-500; fr: https://peptides.cx/fr/library/tb-500; it: https://peptides.cx/it/library/tb-500; es: https://peptides.cx/es/library/tb-500; el: https://peptides.cx/el/library/tb-500; pl: https://peptides.cx/pl/library/tb-500; nl: https://peptides.cx/nl/library/tb-500; cs: https://peptides.cx/cs/library/tb-500; ro: https://peptides.cx/ro/library/tb-500; bg: https://peptides.cx/bg/library/tb-500; fi: https://peptides.cx/fi/library/tb-500; sv: https://peptides.cx/sv/library/tb-500; sk: https://peptides.cx/sk/library/tb-500; lt: https://peptides.cx/lt/library/tb-500 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Thymosin Beta-4, TB4 Category: Recovery / Regeneration Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine for general human use. Research chemical status in most jurisdictions. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A peptide related to the naturally occurring protein Thymosin Beta-4, discussed for recovery and regeneration. Human evidence is limited. What is it: TB-500 is a synthetic fragment associated with Thymosin Beta-4, a protein involved in cell migration and actin regulation. Proposed mechanisms: - Proposed regulation of actin, supporting cell migration - Discussed roles in angiogenesis and tissue repair Human evidence: Limited. Thymosin Beta-4 itself has been studied in some clinical contexts, but the research-market 'TB-500' fragment lacks robust human trials. Animal / preclinical evidence: Animal studies suggest roles in wound healing and cardiac tissue repair. Safety: Human safety data is limited. Material sold on the research market is not quality-assured for human use. Known side effects: - Fatigue reported anecdotally - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review — Applied Sciences (MDPI): https://www.mdpi.com/2076-3417/16/12/6202 --- ## GHK-Cu Name: GHK-Cu Canonical URL: https://peptides.cx/library/ghk-cu Localized URLs: en: https://peptides.cx/library/ghk-cu; de: https://peptides.cx/de/library/ghk-cu; fr: https://peptides.cx/fr/library/ghk-cu; it: https://peptides.cx/it/library/ghk-cu; es: https://peptides.cx/es/library/ghk-cu; el: https://peptides.cx/el/library/ghk-cu; pl: https://peptides.cx/pl/library/ghk-cu; nl: https://peptides.cx/nl/library/ghk-cu; cs: https://peptides.cx/cs/library/ghk-cu; ro: https://peptides.cx/ro/library/ghk-cu; bg: https://peptides.cx/bg/library/ghk-cu; fi: https://peptides.cx/fi/library/ghk-cu; sv: https://peptides.cx/sv/library/ghk-cu; sk: https://peptides.cx/sk/library/ghk-cu; lt: https://peptides.cx/lt/library/ghk-cu Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Copper Peptide, Copper tripeptide-1 Category: Skin / Cosmetic Evidence grade: B (B — Human, limited) Regulatory status: Widely used as a cosmetic ingredient in topical products. Cosmetic use is broadly permitted; injectable use is a separate matter. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A copper-binding tripeptide common in cosmetics. There is reasonable evidence for topical skin benefits; systemic/injected use is far less studied. What is it: GHK-Cu is a naturally occurring copper-binding peptide used extensively in topical skincare formulations. Proposed mechanisms: - Copper delivery relevant to skin remodelling - Discussed effects on collagen and antioxidant pathways Human evidence: Topical cosmetic studies report improvements in skin appearance. Evidence for injected/systemic use is limited. Animal / preclinical evidence: Animal and in-vitro work supports wound-healing and skin-remodelling roles. Safety: Topical cosmetic use is generally well tolerated. Injected use is not a validated cosmetic route and carries different risks. Known side effects: - Topical irritation in some users Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration — BioMed Research International · PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508379/ --- ## KPV Name: KPV Canonical URL: https://peptides.cx/library/kpv Localized URLs: en: https://peptides.cx/library/kpv; de: https://peptides.cx/de/library/kpv; fr: https://peptides.cx/fr/library/kpv; it: https://peptides.cx/it/library/kpv; es: https://peptides.cx/es/library/kpv; el: https://peptides.cx/el/library/kpv; pl: https://peptides.cx/pl/library/kpv; nl: https://peptides.cx/nl/library/kpv; cs: https://peptides.cx/cs/library/kpv; ro: https://peptides.cx/ro/library/kpv; bg: https://peptides.cx/bg/library/kpv; fi: https://peptides.cx/fi/library/kpv; sv: https://peptides.cx/sv/library/kpv; sk: https://peptides.cx/sk/library/kpv; lt: https://peptides.cx/lt/library/kpv Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Lysine-Proline-Valine Category: Inflammation Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine. Research chemical status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A short tripeptide fragment of alpha-MSH discussed in the context of inflammation. Human evidence is limited. What is it: KPV is the C-terminal tripeptide of the alpha-MSH hormone, studied for anti-inflammatory properties. Proposed mechanisms: - Discussed anti-inflammatory signalling - Proposed effects on gut inflammation Human evidence: Very limited human data. Animal / preclinical evidence: Preclinical work suggests anti-inflammatory activity in models of colitis. Safety: Human safety data is limited; research-market purity is unverified. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Inflammatory Bowel Diseases · PubMed: https://pubmed.ncbi.nlm.nih.gov/18092346/ - Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore — Advances in Experimental Medicine and Biology · PubMed: https://pubmed.ncbi.nlm.nih.gov/21222263/ --- ## Semax Name: Semax Canonical URL: https://peptides.cx/library/semax Localized URLs: en: https://peptides.cx/library/semax; de: https://peptides.cx/de/library/semax; fr: https://peptides.cx/fr/library/semax; it: https://peptides.cx/it/library/semax; es: https://peptides.cx/es/library/semax; el: https://peptides.cx/el/library/semax; pl: https://peptides.cx/pl/library/semax; nl: https://peptides.cx/nl/library/semax; cs: https://peptides.cx/cs/library/semax; ro: https://peptides.cx/ro/library/semax; bg: https://peptides.cx/bg/library/semax; fi: https://peptides.cx/fi/library/semax; sv: https://peptides.cx/sv/library/semax; sk: https://peptides.cx/sk/library/semax; lt: https://peptides.cx/lt/library/semax Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: ACTH(4-7) analogue Category: Cognitive Evidence grade: C (C — Early / Preclinical) Regulatory status: Approved/used as a medicine in some countries (e.g. Russia); not approved in the EU/US. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A peptide discussed for cognitive and neuroprotective effects. Approved in some jurisdictions but not others. What is it: Semax is a synthetic peptide derived from an ACTH fragment, studied for nootropic and neuroprotective effects. Proposed mechanisms: - Discussed modulation of BDNF - Proposed neuroprotective signalling Human evidence: Some human studies exist in the countries where it is used clinically; broader independent replication is limited. Animal / preclinical evidence: Preclinical work reports neuroprotective and cognitive effects. Safety: Where used clinically it is intranasal and prescribed; research-market use is unverified. Known side effects: - Nasal irritation with intranasal use reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents — Neurochemical Research · PubMed: https://pubmed.ncbi.nlm.nih.gov/16362768/ - Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats — Genes (Basel) · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC7350263/ --- ## Selank Name: Selank Canonical URL: https://peptides.cx/library/selank Localized URLs: en: https://peptides.cx/library/selank; de: https://peptides.cx/de/library/selank; fr: https://peptides.cx/fr/library/selank; it: https://peptides.cx/it/library/selank; es: https://peptides.cx/es/library/selank; el: https://peptides.cx/el/library/selank; pl: https://peptides.cx/pl/library/selank; nl: https://peptides.cx/nl/library/selank; cs: https://peptides.cx/cs/library/selank; ro: https://peptides.cx/ro/library/selank; bg: https://peptides.cx/bg/library/selank; fi: https://peptides.cx/fi/library/selank; sv: https://peptides.cx/sv/library/selank; sk: https://peptides.cx/sk/library/selank; lt: https://peptides.cx/lt/library/selank Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: TP-7 analogue Category: Cognitive / Mood Evidence grade: C (C — Early / Preclinical) Regulatory status: Used as a medicine in some countries; not approved in the EU/US. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An anxiolytic-discussed peptide analogue. Approved in some jurisdictions, limited independent evidence elsewhere. What is it: Selank is a synthetic analogue of the endogenous peptide tuftsin, studied for anxiolytic effects. Proposed mechanisms: - Discussed effects on GABA and monoamine systems Human evidence: Some regional clinical use; limited independent replication. Animal / preclinical evidence: Preclinical anxiolytic effects reported. Safety: Research-market purity is unverified; not a validated treatment outside its regional approvals. Known side effects: - Nasal irritation with intranasal use reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders — Zh Nevrol Psikhiatr im S.S. Korsakova · PubMed: https://pubmed.ncbi.nlm.nih.gov/25176261/ - Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats — Behavioural Neurology · PubMed: https://pubmed.ncbi.nlm.nih.gov/28280289/ --- ## Epitalon Name: Epitalon Canonical URL: https://peptides.cx/library/epitalon Localized URLs: en: https://peptides.cx/library/epitalon; de: https://peptides.cx/de/library/epitalon; fr: https://peptides.cx/fr/library/epitalon; it: https://peptides.cx/it/library/epitalon; es: https://peptides.cx/es/library/epitalon; el: https://peptides.cx/el/library/epitalon; pl: https://peptides.cx/pl/library/epitalon; nl: https://peptides.cx/nl/library/epitalon; cs: https://peptides.cx/cs/library/epitalon; ro: https://peptides.cx/ro/library/epitalon; bg: https://peptides.cx/bg/library/epitalon; fi: https://peptides.cx/fi/library/epitalon; sv: https://peptides.cx/sv/library/epitalon; sk: https://peptides.cx/sk/library/epitalon; lt: https://peptides.cx/lt/library/epitalon Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Epithalon, AEDG Category: Longevity Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Research chemical status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A tetrapeptide discussed in longevity circles for telomerase-related claims. Human evidence is weak. What is it: Epitalon is a synthetic tetrapeptide studied primarily in Russian gerontology research. Proposed mechanisms: - Proposed effects on telomerase activity - Discussed circadian and pineal effects Human evidence: Sparse and largely from a small number of research groups; independent replication is limited. Animal / preclinical evidence: Some rodent longevity data reported by originating groups. Safety: Human safety data is weak. Claims should be treated with caution. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties — PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/ --- ## MOTS-c Name: MOTS-c Canonical URL: https://peptides.cx/library/mots-c Localized URLs: en: https://peptides.cx/library/mots-c; de: https://peptides.cx/de/library/mots-c; fr: https://peptides.cx/fr/library/mots-c; it: https://peptides.cx/it/library/mots-c; es: https://peptides.cx/es/library/mots-c; el: https://peptides.cx/el/library/mots-c; pl: https://peptides.cx/pl/library/mots-c; nl: https://peptides.cx/nl/library/mots-c; cs: https://peptides.cx/cs/library/mots-c; ro: https://peptides.cx/ro/library/mots-c; bg: https://peptides.cx/bg/library/mots-c; fi: https://peptides.cx/fi/library/mots-c; sv: https://peptides.cx/sv/library/mots-c; sk: https://peptides.cx/sk/library/mots-c; lt: https://peptides.cx/lt/library/mots-c Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Mitochondrial ORF of the 12S rRNA type-c Category: Metabolic Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine. Research chemical status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A mitochondrial-derived peptide discussed for metabolic effects. Mostly preclinical evidence. What is it: MOTS-c is a peptide encoded in mitochondrial DNA, studied for roles in metabolism and exercise physiology. Proposed mechanisms: - Discussed AMPK activation - Proposed metabolic-regulation roles Human evidence: Limited; mostly observational and mechanistic. Animal / preclinical evidence: Rodent studies report effects on insulin sensitivity and metabolism. Safety: Human safety data is limited; research-market material is unverified. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging — PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC9854231/ - MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism — PubMed: https://pubmed.ncbi.nlm.nih.gov/27216708/ --- ## DSIP Name: DSIP Canonical URL: https://peptides.cx/library/dsip Localized URLs: en: https://peptides.cx/library/dsip; de: https://peptides.cx/de/library/dsip; fr: https://peptides.cx/fr/library/dsip; it: https://peptides.cx/it/library/dsip; es: https://peptides.cx/es/library/dsip; el: https://peptides.cx/el/library/dsip; pl: https://peptides.cx/pl/library/dsip; nl: https://peptides.cx/nl/library/dsip; cs: https://peptides.cx/cs/library/dsip; ro: https://peptides.cx/ro/library/dsip; bg: https://peptides.cx/bg/library/dsip; fi: https://peptides.cx/fi/library/dsip; sv: https://peptides.cx/sv/library/dsip; sk: https://peptides.cx/sk/library/dsip; lt: https://peptides.cx/lt/library/dsip Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Delta Sleep-Inducing Peptide Category: Sleep Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Research chemical status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A peptide historically studied for sleep. Human evidence is old and inconsistent. What is it: DSIP is a neuropeptide first described in relation to sleep regulation. Proposed mechanisms: - Discussed effects on sleep architecture and stress hormones Human evidence: Older human studies exist with mixed and inconsistent results. Animal / preclinical evidence: Mixed preclinical findings. Safety: Human safety data is limited and dated. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Delta sleep-inducing peptide (DSIP): a still unresolved riddle — Journal of Neurochemistry · PubMed: https://pubmed.ncbi.nlm.nih.gov/16539679/ - Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs — International Journal of Clinical Pharmacology Research · PubMed: https://pubmed.ncbi.nlm.nih.gov/3583493/ --- ## Ipamorelin Name: Ipamorelin Canonical URL: https://peptides.cx/library/ipamorelin Localized URLs: en: https://peptides.cx/library/ipamorelin; de: https://peptides.cx/de/library/ipamorelin; fr: https://peptides.cx/fr/library/ipamorelin; it: https://peptides.cx/it/library/ipamorelin; es: https://peptides.cx/es/library/ipamorelin; el: https://peptides.cx/el/library/ipamorelin; pl: https://peptides.cx/pl/library/ipamorelin; nl: https://peptides.cx/nl/library/ipamorelin; cs: https://peptides.cx/cs/library/ipamorelin; ro: https://peptides.cx/ro/library/ipamorelin; bg: https://peptides.cx/bg/library/ipamorelin; fi: https://peptides.cx/fi/library/ipamorelin; sv: https://peptides.cx/sv/library/ipamorelin; sk: https://peptides.cx/sk/library/ipamorelin; lt: https://peptides.cx/lt/library/ipamorelin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Growth hormone secretagogue Category: Growth Hormone Secretagogue Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine for general use. Research chemical status. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A growth-hormone secretagogue discussed for recovery and body composition. Limited human trial evidence. What is it: Ipamorelin is a selective growth-hormone secretagogue peptide. Proposed mechanisms: - Stimulation of growth-hormone release via ghrelin-receptor pathways Human evidence: Some early clinical study history; not an approved therapy. Animal / preclinical evidence: Preclinical GH-release effects documented. Safety: Hormonal effects carry real risks; not a validated therapy. Professional supervision matters for anything hormonal. Known side effects: - Water retention reported - Headache reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Growth hormone secretagogues: history, mechanism of action, and clinical development — JCSM Rapid Communications (Wiley): https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 --- ## CJC-1295 Name: CJC-1295 Canonical URL: https://peptides.cx/library/cjc-1295 Localized URLs: en: https://peptides.cx/library/cjc-1295; de: https://peptides.cx/de/library/cjc-1295; fr: https://peptides.cx/fr/library/cjc-1295; it: https://peptides.cx/it/library/cjc-1295; es: https://peptides.cx/es/library/cjc-1295; el: https://peptides.cx/el/library/cjc-1295; pl: https://peptides.cx/pl/library/cjc-1295; nl: https://peptides.cx/nl/library/cjc-1295; cs: https://peptides.cx/cs/library/cjc-1295; ro: https://peptides.cx/ro/library/cjc-1295; bg: https://peptides.cx/bg/library/cjc-1295; fi: https://peptides.cx/fi/library/cjc-1295; sv: https://peptides.cx/sv/library/cjc-1295; sk: https://peptides.cx/sk/library/cjc-1295; lt: https://peptides.cx/lt/library/cjc-1295 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: GRF analogue Category: Growth Hormone Secretagogue Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine for general use. Research chemical status. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A growth-hormone-releasing factor analogue, often discussed alongside Ipamorelin. Limited human evidence. What is it: CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Proposed mechanisms: - Stimulation of endogenous growth-hormone release Human evidence: Limited early clinical history; not an approved therapy. Animal / preclinical evidence: Preclinical GH-axis effects documented. Safety: Hormonal effects carry real risks; not a validated therapy. Known side effects: - Injection-site reactions reported - Water retention reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults — J Clin Endocrinol Metab · PubMed: https://pubmed.ncbi.nlm.nih.gov/16352683/ - Pulsatile secretion of GH persists during continuous stimulation by CJC-1295 — J Clin Endocrinol Metab · PubMed: https://pubmed.ncbi.nlm.nih.gov/17018654/ --- ## AOD-9604 Name: AOD-9604 Canonical URL: https://peptides.cx/library/aod-9604 Localized URLs: en: https://peptides.cx/library/aod-9604; de: https://peptides.cx/de/library/aod-9604; fr: https://peptides.cx/fr/library/aod-9604; it: https://peptides.cx/it/library/aod-9604; es: https://peptides.cx/es/library/aod-9604; el: https://peptides.cx/el/library/aod-9604; pl: https://peptides.cx/pl/library/aod-9604; nl: https://peptides.cx/nl/library/aod-9604; cs: https://peptides.cx/cs/library/aod-9604; ro: https://peptides.cx/ro/library/aod-9604; bg: https://peptides.cx/bg/library/aod-9604; fi: https://peptides.cx/fi/library/aod-9604; sv: https://peptides.cx/sv/library/aod-9604; sk: https://peptides.cx/sk/library/aod-9604; lt: https://peptides.cx/lt/library/aod-9604 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: hGH fragment 176-191 Category: Metabolic Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved weight-loss medicine; clinical development did not lead to approval. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A growth-hormone fragment once investigated for fat loss. Clinical trials did not lead to approval. What is it: AOD-9604 is a fragment of human growth hormone investigated for metabolic effects. Proposed mechanisms: - Discussed effects on lipolysis without the full GH profile Human evidence: Clinical trials for obesity did not demonstrate sufficient efficacy for approval. Animal / preclinical evidence: Some preclinical lipolytic effects reported. Safety: Not an approved therapy; efficacy for fat loss is not established. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone — Hormone Research · PubMed: https://pubmed.ncbi.nlm.nih.gov/11146367/ --- ## Melanotan I Name: Melanotan I Canonical URL: https://peptides.cx/library/melanotan-1 Localized URLs: en: https://peptides.cx/library/melanotan-1; de: https://peptides.cx/de/library/melanotan-1; fr: https://peptides.cx/fr/library/melanotan-1; it: https://peptides.cx/it/library/melanotan-1; es: https://peptides.cx/es/library/melanotan-1; el: https://peptides.cx/el/library/melanotan-1; pl: https://peptides.cx/pl/library/melanotan-1; nl: https://peptides.cx/nl/library/melanotan-1; cs: https://peptides.cx/cs/library/melanotan-1; ro: https://peptides.cx/ro/library/melanotan-1; bg: https://peptides.cx/bg/library/melanotan-1; fi: https://peptides.cx/fi/library/melanotan-1; sv: https://peptides.cx/sv/library/melanotan-1; sk: https://peptides.cx/sk/library/melanotan-1; lt: https://peptides.cx/lt/library/melanotan-1 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Afamelanotide (related) Category: Pigmentation Evidence grade: B (B — Human, limited) Regulatory status: A related compound (afamelanotide) is an approved medicine for a rare condition; research-market Melanotan I is not. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A melanocortin agonist related to an approved medicine. Research-market use is unregulated and carries risks. What is it: Melanotan I is a synthetic analogue of alpha-MSH affecting pigmentation. Proposed mechanisms: - Melanocortin-1 receptor agonism affecting melanin production Human evidence: The related approved drug has clinical evidence for a specific rare condition; general research-market use does not. Animal / preclinical evidence: Melanocortin effects well characterised preclinically. Safety: Unregulated research-market use carries risks including effects on existing moles; dermatological monitoring matters. Known side effects: - Nausea reported - Darkening of moles/freckles reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Scenesse (afamelanotide) — European Public Assessment Report — European Medicines Agency: https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse - SCENESSE (afamelanotide) implant — Prescribing Information — U.S. FDA · DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48 --- ## Melanotan II Name: Melanotan II Canonical URL: https://peptides.cx/library/melanotan-2 Localized URLs: en: https://peptides.cx/library/melanotan-2; de: https://peptides.cx/de/library/melanotan-2; fr: https://peptides.cx/fr/library/melanotan-2; it: https://peptides.cx/it/library/melanotan-2; es: https://peptides.cx/es/library/melanotan-2; el: https://peptides.cx/el/library/melanotan-2; pl: https://peptides.cx/pl/library/melanotan-2; nl: https://peptides.cx/nl/library/melanotan-2; cs: https://peptides.cx/cs/library/melanotan-2; ro: https://peptides.cx/ro/library/melanotan-2; bg: https://peptides.cx/bg/library/melanotan-2; fi: https://peptides.cx/fi/library/melanotan-2; sv: https://peptides.cx/sv/library/melanotan-2; sk: https://peptides.cx/sk/library/melanotan-2; lt: https://peptides.cx/lt/library/melanotan-2 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: MT-2 Category: Pigmentation Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine. Sale for human use is restricted in many countries. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A non-selective melanocortin agonist widely flagged by regulators for safety concerns. What is it: Melanotan II is a synthetic melanocortin agonist affecting pigmentation and other pathways. Proposed mechanisms: - Non-selective melanocortin-receptor agonism Human evidence: No approval; multiple regulator safety warnings exist. Animal / preclinical evidence: Melanocortin effects characterised preclinically. Safety: Regulators have issued safety warnings. Effects on moles, blood pressure, and other systems are of concern. Known side effects: - Nausea - Flushing - Darkening of moles reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — Int J Oral Maxillofac Surg · PubMed: https://pubmed.ncbi.nlm.nih.gov/40210573/ - Melanotan II injection resulting in systemic toxicity and rhabdomyolysis — Clinical Toxicology · PubMed: https://pubmed.ncbi.nlm.nih.gov/23121206/ --- ## Thymosin Alpha-1 Name: Thymosin Alpha-1 Canonical URL: https://peptides.cx/library/thymosin-alpha-1 Localized URLs: en: https://peptides.cx/library/thymosin-alpha-1; de: https://peptides.cx/de/library/thymosin-alpha-1; fr: https://peptides.cx/fr/library/thymosin-alpha-1; it: https://peptides.cx/it/library/thymosin-alpha-1; es: https://peptides.cx/es/library/thymosin-alpha-1; el: https://peptides.cx/el/library/thymosin-alpha-1; pl: https://peptides.cx/pl/library/thymosin-alpha-1; nl: https://peptides.cx/nl/library/thymosin-alpha-1; cs: https://peptides.cx/cs/library/thymosin-alpha-1; ro: https://peptides.cx/ro/library/thymosin-alpha-1; bg: https://peptides.cx/bg/library/thymosin-alpha-1; fi: https://peptides.cx/fi/library/thymosin-alpha-1; sv: https://peptides.cx/sv/library/thymosin-alpha-1; sk: https://peptides.cx/sk/library/thymosin-alpha-1; lt: https://peptides.cx/lt/library/thymosin-alpha-1 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Ta1, Thymalfasin Category: Immune Evidence grade: B (B — Human, limited) Regulatory status: Approved as a medicine (thymalfasin) in some countries for specific indications; not universally approved. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An immune-modulating peptide approved in some countries for specific conditions. What is it: Thymosin Alpha-1 is a peptide involved in immune regulation, marketed as thymalfasin in some regions. Proposed mechanisms: - Immune modulation, including effects on T-cell function Human evidence: Clinical evidence exists for specific approved indications in the countries where it is registered. Animal / preclinical evidence: Immune-modulating effects documented preclinically. Safety: Where approved it is prescribed and monitored; research-market use is unverified. Known side effects: - Injection-site reactions reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A Reappraisal of Thymosin Alpha1 in Cancer Therapy — Frontiers in Oncology · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC6742685/ - Zadaxin (thymosin alpha1) for the treatment of viral hepatitis — Expert Opinion on Investigational Drugs · PubMed: https://pubmed.ncbi.nlm.nih.gov/15992078/ --- ## LL-37 Name: LL-37 Canonical URL: https://peptides.cx/library/ll-37 Localized URLs: en: https://peptides.cx/library/ll-37; de: https://peptides.cx/de/library/ll-37; fr: https://peptides.cx/fr/library/ll-37; it: https://peptides.cx/it/library/ll-37; es: https://peptides.cx/es/library/ll-37; el: https://peptides.cx/el/library/ll-37; pl: https://peptides.cx/pl/library/ll-37; nl: https://peptides.cx/nl/library/ll-37; cs: https://peptides.cx/cs/library/ll-37; ro: https://peptides.cx/ro/library/ll-37; bg: https://peptides.cx/bg/library/ll-37; fi: https://peptides.cx/fi/library/ll-37; sv: https://peptides.cx/sv/library/ll-37; sk: https://peptides.cx/sk/library/ll-37; lt: https://peptides.cx/lt/library/ll-37 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Cathelicidin fragment Category: Antimicrobial / Immune Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine. Research chemical status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An antimicrobial peptide studied for immune and antimicrobial roles. Mostly preclinical. What is it: LL-37 is a human cathelicidin-derived antimicrobial peptide. Proposed mechanisms: - Antimicrobial activity - Immune-modulating roles Human evidence: Limited; largely mechanistic and preclinical. Animal / preclinical evidence: Antimicrobial and immune effects reported. Safety: Human safety data is limited; research-market material is unverified. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - LL-37, the only human member of the cathelicidin family of antimicrobial peptides — Biochimica et Biophysica Acta · PubMed: https://pubmed.ncbi.nlm.nih.gov/16716248/ - Spotlight on Human LL-37, an Immunomodulatory Peptide with Promising Cell-Penetrating Properties — Pharmaceuticals (Basel) · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC4034075/ --- ## Kisspeptin-10 Name: Kisspeptin-10 Canonical URL: https://peptides.cx/library/kisspeptin-10 Localized URLs: en: https://peptides.cx/library/kisspeptin-10; de: https://peptides.cx/de/library/kisspeptin-10; fr: https://peptides.cx/fr/library/kisspeptin-10; it: https://peptides.cx/it/library/kisspeptin-10; es: https://peptides.cx/es/library/kisspeptin-10; el: https://peptides.cx/el/library/kisspeptin-10; pl: https://peptides.cx/pl/library/kisspeptin-10; nl: https://peptides.cx/nl/library/kisspeptin-10; cs: https://peptides.cx/cs/library/kisspeptin-10; ro: https://peptides.cx/ro/library/kisspeptin-10; bg: https://peptides.cx/bg/library/kisspeptin-10; fi: https://peptides.cx/fi/library/kisspeptin-10; sv: https://peptides.cx/sv/library/kisspeptin-10; sk: https://peptides.cx/sk/library/kisspeptin-10; lt: https://peptides.cx/lt/library/kisspeptin-10 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: KP-10 Category: Endocrine Evidence grade: B (B — Human, limited) Regulatory status: Investigational; used in some clinical research settings. Not a general-use medicine. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A reproductive-hormone-axis peptide studied in clinical research. Not a consumer product. What is it: Kisspeptin-10 is a peptide central to the regulation of reproductive hormones. Proposed mechanisms: - Stimulation of GnRH and downstream reproductive hormones Human evidence: Studied in controlled clinical research on reproductive endocrinology. Animal / preclinical evidence: Well-characterised roles in reproductive physiology. Safety: Affects the reproductive hormone axis; only appropriate under clinical/research supervision. Known side effects: - Hormonal effects; context-dependent Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men — J Clin Endocrinol Metab · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC3380939/ - The kisspeptin-GnRH pathway in human reproductive health and disease — Human Reproduction Update · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC4063702/ --- ## GHRP-2 Name: GHRP-2 Canonical URL: https://peptides.cx/library/ghrp-2 Localized URLs: en: https://peptides.cx/library/ghrp-2; de: https://peptides.cx/de/library/ghrp-2; fr: https://peptides.cx/fr/library/ghrp-2; it: https://peptides.cx/it/library/ghrp-2; es: https://peptides.cx/es/library/ghrp-2; el: https://peptides.cx/el/library/ghrp-2; pl: https://peptides.cx/pl/library/ghrp-2; nl: https://peptides.cx/nl/library/ghrp-2; cs: https://peptides.cx/cs/library/ghrp-2; ro: https://peptides.cx/ro/library/ghrp-2; bg: https://peptides.cx/bg/library/ghrp-2; fi: https://peptides.cx/fi/library/ghrp-2; sv: https://peptides.cx/sv/library/ghrp-2; sk: https://peptides.cx/sk/library/ghrp-2; lt: https://peptides.cx/lt/library/ghrp-2 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Growth Hormone Releasing Peptide-2 Category: Growth Hormone Secretagogue Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine for general use. Research chemical status. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A growth-hormone-releasing peptide with limited human evidence and hormonal risks. What is it: GHRP-2 is a synthetic growth-hormone secretagogue. Proposed mechanisms: - Ghrelin-receptor-mediated growth-hormone release Human evidence: Some pharmacological study history; not an approved therapy. Animal / preclinical evidence: Preclinical GH-release effects documented. Safety: Hormonal effects carry real risks; not a validated therapy. Known side effects: - Increased appetite - Water retention reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency — European Journal of Endocrinology · PubMed: https://pubmed.ncbi.nlm.nih.gov/17609397/ - Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN — Drugs in R&D · PubMed: https://pubmed.ncbi.nlm.nih.gov/15230633/ --- ## GHRP-6 Name: GHRP-6 Canonical URL: https://peptides.cx/library/ghrp-6 Localized URLs: en: https://peptides.cx/library/ghrp-6; de: https://peptides.cx/de/library/ghrp-6; fr: https://peptides.cx/fr/library/ghrp-6; it: https://peptides.cx/it/library/ghrp-6; es: https://peptides.cx/es/library/ghrp-6; el: https://peptides.cx/el/library/ghrp-6; pl: https://peptides.cx/pl/library/ghrp-6; nl: https://peptides.cx/nl/library/ghrp-6; cs: https://peptides.cx/cs/library/ghrp-6; ro: https://peptides.cx/ro/library/ghrp-6; bg: https://peptides.cx/bg/library/ghrp-6; fi: https://peptides.cx/fi/library/ghrp-6; sv: https://peptides.cx/sv/library/ghrp-6; sk: https://peptides.cx/sk/library/ghrp-6; lt: https://peptides.cx/lt/library/ghrp-6 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Growth Hormone Releasing Peptide-6 Category: Growth Hormone Secretagogue Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine for general use. Research chemical status. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A growth-hormone-releasing peptide known for strong appetite effects. Limited human evidence. What is it: GHRP-6 is a synthetic growth-hormone secretagogue. Proposed mechanisms: - Ghrelin-receptor-mediated growth-hormone release Human evidence: Some pharmacological study history; not an approved therapy. Animal / preclinical evidence: Preclinical GH-release and appetite effects documented. Safety: Hormonal effects carry real risks; not a validated therapy. Known side effects: - Strong appetite increase - Water retention reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man — Neuroendocrinology · PubMed: https://pubmed.ncbi.nlm.nih.gov/7617137/ - Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation — J Clin Endocrinol Metab · PubMed: https://pubmed.ncbi.nlm.nih.gov/9543138/ --- ## Semaglutide Name: Semaglutide Canonical URL: https://peptides.cx/library/semaglutide Localized URLs: en: https://peptides.cx/library/semaglutide; de: https://peptides.cx/de/library/semaglutide; fr: https://peptides.cx/fr/library/semaglutide; it: https://peptides.cx/it/library/semaglutide; es: https://peptides.cx/es/library/semaglutide; el: https://peptides.cx/el/library/semaglutide; pl: https://peptides.cx/pl/library/semaglutide; nl: https://peptides.cx/nl/library/semaglutide; cs: https://peptides.cx/cs/library/semaglutide; ro: https://peptides.cx/ro/library/semaglutide; bg: https://peptides.cx/bg/library/semaglutide; fi: https://peptides.cx/fi/library/semaglutide; sv: https://peptides.cx/sv/library/semaglutide; sk: https://peptides.cx/sk/library/semaglutide; lt: https://peptides.cx/lt/library/semaglutide Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Ozempic, Wegovy, Rybelsus Category: Metabolic Evidence grade: A (A — Approved / Strong) Regulatory status: Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A GLP-1 receptor agonist approved for diabetes and weight management. This page is informational only and not a source or promotion. What is it: Semaglutide is a long-acting GLP-1 receptor agonist. It is an approved prescription medicine used under medical supervision. Proposed mechanisms: - GLP-1 receptor agonism enhancing glucose-dependent insulin secretion - Slowed gastric emptying and central appetite suppression Human evidence: Strong clinical trial evidence and regulatory approval for glycemic control and weight loss. Animal / preclinical evidence: Extensively characterised in preclinical models. Safety: A prescription medicine that must be used under medical supervision, with a prescribing information document that lists its risks in full. Research-market material is not the licensed product: it is not quality-assured, not dispensed by a pharmacist, and carries no prescribing information. Obtaining or using it without a prescription is unlawful in many countries. Known side effects: - Nausea - Gastrointestinal effects - See approved prescribing information Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems in Adults with Obesity or Overweight (semaglutide) — U.S. Food & Drug Administration: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or --- ## Tirzepatide Name: Tirzepatide Canonical URL: https://peptides.cx/library/tirzepatide Localized URLs: en: https://peptides.cx/library/tirzepatide; de: https://peptides.cx/de/library/tirzepatide; fr: https://peptides.cx/fr/library/tirzepatide; it: https://peptides.cx/it/library/tirzepatide; es: https://peptides.cx/es/library/tirzepatide; el: https://peptides.cx/el/library/tirzepatide; pl: https://peptides.cx/pl/library/tirzepatide; nl: https://peptides.cx/nl/library/tirzepatide; cs: https://peptides.cx/cs/library/tirzepatide; ro: https://peptides.cx/ro/library/tirzepatide; bg: https://peptides.cx/bg/library/tirzepatide; fi: https://peptides.cx/fi/library/tirzepatide; sv: https://peptides.cx/sv/library/tirzepatide; sk: https://peptides.cx/sk/library/tirzepatide; lt: https://peptides.cx/lt/library/tirzepatide Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist Category: Metabolic Evidence grade: A (A — Approved / Strong) Regulatory status: Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A dual GIP and GLP-1 receptor agonist approved for diabetes and weight management. Informational only — not a source or promotion. What is it: Tirzepatide is a dual GIP/GLP-1 receptor agonist and an approved prescription medicine used under medical supervision. Proposed mechanisms: - Dual agonism of the GIP and GLP-1 receptors - Improved insulin sensitivity, slowed gastric emptying, and appetite regulation Human evidence: Strong clinical trial evidence and regulatory approval for glycemic control and weight loss. Animal / preclinical evidence: Extensively characterised in preclinical models. Safety: A prescription medicine that must be used under medical supervision, with a prescribing information document that lists its risks in full. Research-market material is not the licensed product: it is not quality-assured, not dispensed by a pharmacist, and carries no prescribing information. Obtaining or using it without a prescription is unlawful in many countries. Known side effects: - Nausea - Gastrointestinal effects - See approved prescribing information Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Drug Trials Snapshots: Mounjaro (tirzepatide) — U.S. Food & Drug Administration: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mounjaro - FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) — U.S. Food & Drug Administration: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management --- ## Retatrutide Name: Retatrutide Canonical URL: https://peptides.cx/library/retatrutide Localized URLs: en: https://peptides.cx/library/retatrutide; de: https://peptides.cx/de/library/retatrutide; fr: https://peptides.cx/fr/library/retatrutide; it: https://peptides.cx/it/library/retatrutide; es: https://peptides.cx/es/library/retatrutide; el: https://peptides.cx/el/library/retatrutide; pl: https://peptides.cx/pl/library/retatrutide; nl: https://peptides.cx/nl/library/retatrutide; cs: https://peptides.cx/cs/library/retatrutide; ro: https://peptides.cx/ro/library/retatrutide; bg: https://peptides.cx/bg/library/retatrutide; fi: https://peptides.cx/fi/library/retatrutide; sv: https://peptides.cx/sv/library/retatrutide; sk: https://peptides.cx/sk/library/retatrutide; lt: https://peptides.cx/lt/library/retatrutide Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: LY3437943, GGG triple agonist Category: Metabolic Evidence grade: B (B — Human, limited) Regulatory status: Investigational — not an approved medicine. Under clinical evaluation; not for unsupervised research-market use. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An investigational triple agonist (GLP-1, GIP, and glucagon receptors) in clinical trials for obesity and metabolic disease. Informational only — not a source or promotion. What is it: Retatrutide is an investigational triple hormone-receptor agonist acting on GLP-1, GIP, and glucagon receptors. It is not an approved medicine. Proposed mechanisms: - Agonism of GLP-1, GIP, and glucagon receptors - Combined appetite suppression, insulin regulation, and increased energy expenditure Human evidence: Phase 2 trials report substantial weight loss; phase 3 evaluation ongoing. Not yet approved. Animal / preclinical evidence: Characterised in preclinical metabolic models. Safety: An investigational compound with no regulatory approval anywhere, so no authority has assessed its risk-benefit profile and no approved prescribing information exists. Long-term safety in humans is unknown, and research-market material is not quality-assured. Known side effects: - Nausea - Gastrointestinal effects - Increased heart rate - Under investigation Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine · PubMed: https://pubmed.ncbi.nlm.nih.gov/37366315/ - Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial — The Lancet · PubMed: https://pubmed.ncbi.nlm.nih.gov/37385280/ --- ## Liraglutide Name: Liraglutide Canonical URL: https://peptides.cx/library/liraglutide Localized URLs: en: https://peptides.cx/library/liraglutide; de: https://peptides.cx/de/library/liraglutide; fr: https://peptides.cx/fr/library/liraglutide; it: https://peptides.cx/it/library/liraglutide; es: https://peptides.cx/es/library/liraglutide; el: https://peptides.cx/el/library/liraglutide; pl: https://peptides.cx/pl/library/liraglutide; nl: https://peptides.cx/nl/library/liraglutide; cs: https://peptides.cx/cs/library/liraglutide; ro: https://peptides.cx/ro/library/liraglutide; bg: https://peptides.cx/bg/library/liraglutide; fi: https://peptides.cx/fi/library/liraglutide; sv: https://peptides.cx/sv/library/liraglutide; sk: https://peptides.cx/sk/library/liraglutide; lt: https://peptides.cx/lt/library/liraglutide Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: Victoza, Saxenda Category: Metabolic Evidence grade: A (A — Approved / Strong) Regulatory status: Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A daily GLP-1 receptor agonist approved for diabetes and weight management. Informational only — not a source or promotion. What is it: Liraglutide is a GLP-1 receptor agonist and an approved prescription medicine used under medical supervision. Proposed mechanisms: - GLP-1 receptor agonism enhancing glucose-dependent insulin secretion - Slowed gastric emptying and central appetite regulation Human evidence: Strong clinical trial evidence and regulatory approval for glycemic control and weight loss. Animal / preclinical evidence: Extensively characterised in preclinical models. Safety: A prescription medicine that must be used under medical supervision, with a prescribing information document that lists its risks in full. Research-market material is not the licensed product: it is not quality-assured, not dispensed by a pharmacist, and carries no prescribing information. Obtaining or using it without a prescription is unlawful in many countries. Known side effects: - Nausea - Gastrointestinal effects - See approved prescribing information Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — New England Journal of Medicine · PubMed: https://pubmed.ncbi.nlm.nih.gov/26132939/ - SAXENDA (liraglutide injection) — Prescribing Information — U.S. FDA · DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 --- ## Tesamorelin Name: Tesamorelin Canonical URL: https://peptides.cx/library/tesamorelin Localized URLs: en: https://peptides.cx/library/tesamorelin; de: https://peptides.cx/de/library/tesamorelin; fr: https://peptides.cx/fr/library/tesamorelin; it: https://peptides.cx/it/library/tesamorelin; es: https://peptides.cx/es/library/tesamorelin; el: https://peptides.cx/el/library/tesamorelin; pl: https://peptides.cx/pl/library/tesamorelin; nl: https://peptides.cx/nl/library/tesamorelin; cs: https://peptides.cx/cs/library/tesamorelin; ro: https://peptides.cx/ro/library/tesamorelin; bg: https://peptides.cx/bg/library/tesamorelin; fi: https://peptides.cx/fi/library/tesamorelin; sv: https://peptides.cx/sv/library/tesamorelin; sk: https://peptides.cx/sk/library/tesamorelin; lt: https://peptides.cx/lt/library/tesamorelin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Egrifta, TH9507 Category: Growth Hormone Secretagogue Evidence grade: B (B — Human, limited) Regulatory status: Approved as a prescription medicine (Egrifta) for HIV-associated lipodystrophy in some jurisdictions; prescription-only. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A GHRH analogue approved as a prescription medicine for a specific condition. Research-market use is unapproved and unsupervised. What is it: Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone. Proposed mechanisms: - Stimulates endogenous growth-hormone release via the GHRH pathway Human evidence: Clinical evidence supports its approved indication; other uses are not established. Animal / preclinical evidence: GH-axis effects characterised preclinically. Safety: A prescription medicine with real hormonal effects; must be used under medical supervision. Not for unsupervised use. Known side effects: - Injection-site reactions - Joint pain - Fluid retention reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - EGRIFTA SV (tesamorelin) Prescribing Information — U.S. FDA · accessdata: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf --- ## Sermorelin Name: Sermorelin Canonical URL: https://peptides.cx/library/sermorelin Localized URLs: en: https://peptides.cx/library/sermorelin; de: https://peptides.cx/de/library/sermorelin; fr: https://peptides.cx/fr/library/sermorelin; it: https://peptides.cx/it/library/sermorelin; es: https://peptides.cx/es/library/sermorelin; el: https://peptides.cx/el/library/sermorelin; pl: https://peptides.cx/pl/library/sermorelin; nl: https://peptides.cx/nl/library/sermorelin; cs: https://peptides.cx/cs/library/sermorelin; ro: https://peptides.cx/ro/library/sermorelin; bg: https://peptides.cx/bg/library/sermorelin; fi: https://peptides.cx/fi/library/sermorelin; sv: https://peptides.cx/sv/library/sermorelin; sk: https://peptides.cx/sk/library/sermorelin; lt: https://peptides.cx/lt/library/sermorelin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: GRF 1-29 Category: Growth Hormone Secretagogue Evidence grade: C (C — Early / Preclinical) Regulatory status: Previously marketed as a medicine for diagnostic/therapeutic use; availability and status vary by country. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A GHRH fragment historically used clinically, now common in research and compounding contexts. What is it: Sermorelin is a peptide corresponding to the first 29 amino acids of GHRH. Proposed mechanisms: - Stimulates pituitary growth-hormone release Human evidence: Some historical clinical use; modern research-market use is not a validated therapy. Animal / preclinical evidence: GH-release effects documented. Safety: Hormonal effects carry real risks; supervision matters for anything affecting the GH axis. Known side effects: - Injection-site reactions - Flushing reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A comparative study of GH and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency — Acta Paediatrica Supplement · PubMed: https://pubmed.ncbi.nlm.nih.gov/8329830/ - Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of GH secretion in healthy subjects — Acta Paediatrica Supplement · PubMed: https://pubmed.ncbi.nlm.nih.gov/8329825/ --- ## Hexarelin Name: Hexarelin Canonical URL: https://peptides.cx/library/hexarelin Localized URLs: en: https://peptides.cx/library/hexarelin; de: https://peptides.cx/de/library/hexarelin; fr: https://peptides.cx/fr/library/hexarelin; it: https://peptides.cx/it/library/hexarelin; es: https://peptides.cx/es/library/hexarelin; el: https://peptides.cx/el/library/hexarelin; pl: https://peptides.cx/pl/library/hexarelin; nl: https://peptides.cx/nl/library/hexarelin; cs: https://peptides.cx/cs/library/hexarelin; ro: https://peptides.cx/ro/library/hexarelin; bg: https://peptides.cx/bg/library/hexarelin; fi: https://peptides.cx/fi/library/hexarelin; sv: https://peptides.cx/sv/library/hexarelin; sk: https://peptides.cx/sk/library/hexarelin; lt: https://peptides.cx/lt/library/hexarelin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Examorelin Category: Growth Hormone Secretagogue Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine for general use. Research chemical status. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A potent growth-hormone-releasing peptide with limited human evidence and hormonal risks. What is it: Hexarelin is a synthetic hexapeptide growth-hormone secretagogue. Proposed mechanisms: - Ghrelin-receptor-mediated GH release - Discussed cardiac effects Human evidence: Limited pharmacological study history; not an approved therapy. Animal / preclinical evidence: GH-release and cardiovascular effects reported preclinically. Safety: Hormonal effects and potential desensitisation; not a validated therapy. Known side effects: - Water retention - Prolactin/cortisol effects reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans — Journal of Endocrinological Investigation · PubMed: https://pubmed.ncbi.nlm.nih.gov/10342360/ - The cardiovascular action of hexarelin — Journal of Geriatric Cardiology · PubMed: https://pubmed.ncbi.nlm.nih.gov/25278975/ --- ## MGF / PEG-MGF Name: MGF / PEG-MGF Canonical URL: https://peptides.cx/library/mgf Localized URLs: en: https://peptides.cx/library/mgf; de: https://peptides.cx/de/library/mgf; fr: https://peptides.cx/fr/library/mgf; it: https://peptides.cx/it/library/mgf; es: https://peptides.cx/es/library/mgf; el: https://peptides.cx/el/library/mgf; pl: https://peptides.cx/pl/library/mgf; nl: https://peptides.cx/nl/library/mgf; cs: https://peptides.cx/cs/library/mgf; ro: https://peptides.cx/ro/library/mgf; bg: https://peptides.cx/bg/library/mgf; fi: https://peptides.cx/fi/library/mgf; sv: https://peptides.cx/sv/library/mgf; sk: https://peptides.cx/sk/library/mgf; lt: https://peptides.cx/lt/library/mgf Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Mechano Growth Factor, IGF-1Ec Category: Growth Factor Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Research chemical status; prohibited in sport. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A splice variant of IGF-1 discussed for muscle repair. Human evidence is minimal. What is it: MGF is a mechano-growth-factor splice variant of IGF-1; PEG-MGF is a pegylated form. Proposed mechanisms: - Discussed roles in muscle satellite-cell activation Human evidence: Minimal; largely mechanistic and anecdotal. Animal / preclinical evidence: Some muscle-repair signalling reported. Safety: Growth-factor signalling carries theoretical risks; unverified research-market material. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration — Endocrinology · PubMed: https://pubmed.ncbi.nlm.nih.gov/20130113/ - Insulin-Like Growth Factor I (IGF-1) Ec/Mechano Growth Factor — A Splice Variant of IGF-1 within the Growth Plate — PLoS One · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC3795771/ --- ## IGF-1 LR3 Name: IGF-1 LR3 Canonical URL: https://peptides.cx/library/igf-1-lr3 Localized URLs: en: https://peptides.cx/library/igf-1-lr3; de: https://peptides.cx/de/library/igf-1-lr3; fr: https://peptides.cx/fr/library/igf-1-lr3; it: https://peptides.cx/it/library/igf-1-lr3; es: https://peptides.cx/es/library/igf-1-lr3; el: https://peptides.cx/el/library/igf-1-lr3; pl: https://peptides.cx/pl/library/igf-1-lr3; nl: https://peptides.cx/nl/library/igf-1-lr3; cs: https://peptides.cx/cs/library/igf-1-lr3; ro: https://peptides.cx/ro/library/igf-1-lr3; bg: https://peptides.cx/bg/library/igf-1-lr3; fi: https://peptides.cx/fi/library/igf-1-lr3; sv: https://peptides.cx/sv/library/igf-1-lr3; sk: https://peptides.cx/sk/library/igf-1-lr3; lt: https://peptides.cx/lt/library/igf-1-lr3 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Long R3 IGF-1 Category: Growth Factor Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine for general use; prohibited in sport. Research chemical status. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A long-acting IGF-1 analogue with significant hormonal/growth-factor risks and little human safety data. What is it: IGF-1 LR3 is a modified insulin-like growth factor 1 with extended half-life. Proposed mechanisms: - IGF-1 receptor agonism affecting growth and metabolism Human evidence: No approval for the research-market form; safety data is lacking. Animal / preclinical evidence: Growth and metabolic effects documented. Safety: Potent growth-factor with risks including hypoglycaemia and theoretical proliferative concerns. Not a validated therapy. Known side effects: - Hypoglycaemia risk - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells — Molecular Biotechnology · PubMed: https://pubmed.ncbi.nlm.nih.gov/17172665/ - Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes — Drug Testing and Analysis · PubMed: https://pubmed.ncbi.nlm.nih.gov/33587816/ --- ## PT-141 (Bremelanotide) Name: PT-141 (Bremelanotide) Canonical URL: https://peptides.cx/library/pt-141 Localized URLs: en: https://peptides.cx/library/pt-141; de: https://peptides.cx/de/library/pt-141; fr: https://peptides.cx/fr/library/pt-141; it: https://peptides.cx/it/library/pt-141; es: https://peptides.cx/es/library/pt-141; el: https://peptides.cx/el/library/pt-141; pl: https://peptides.cx/pl/library/pt-141; nl: https://peptides.cx/nl/library/pt-141; cs: https://peptides.cx/cs/library/pt-141; ro: https://peptides.cx/ro/library/pt-141; bg: https://peptides.cx/bg/library/pt-141; fi: https://peptides.cx/fi/library/pt-141; sv: https://peptides.cx/sv/library/pt-141; sk: https://peptides.cx/sk/library/pt-141; lt: https://peptides.cx/lt/library/pt-141 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Bremelanotide, Vyleesi Category: Sexual Health Evidence grade: B (B — Human, limited) Regulatory status: Approved as a prescription medicine (Vyleesi) for a specific indication in some jurisdictions; prescription-only. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A melanocortin agonist approved as a prescription medicine. Research-market use is unregulated. What is it: PT-141 is a melanocortin-receptor agonist related to the pigmentation peptides. Proposed mechanisms: - Central melanocortin-receptor agonism Human evidence: Clinical evidence supports its approved indication. Animal / preclinical evidence: Melanocortin effects characterised. Safety: Can affect blood pressure and cause nausea; prescription medicine that needs supervision. Known side effects: - Nausea - Flushing - Transient blood-pressure changes Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - VYLEESI (bremelanotide injection) Prescribing Information — Initial U.S. Approval 2019 — U.S. FDA · accessdata: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf - Label: VYLEESI (bremelanotide injection) — DailyMed (U.S. National Library of Medicine): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf --- ## Follistatin Name: Follistatin Canonical URL: https://peptides.cx/library/follistatin Localized URLs: en: https://peptides.cx/library/follistatin; de: https://peptides.cx/de/library/follistatin; fr: https://peptides.cx/fr/library/follistatin; it: https://peptides.cx/it/library/follistatin; es: https://peptides.cx/es/library/follistatin; el: https://peptides.cx/el/library/follistatin; pl: https://peptides.cx/pl/library/follistatin; nl: https://peptides.cx/nl/library/follistatin; cs: https://peptides.cx/cs/library/follistatin; ro: https://peptides.cx/ro/library/follistatin; bg: https://peptides.cx/bg/library/follistatin; fi: https://peptides.cx/fi/library/follistatin; sv: https://peptides.cx/sv/library/follistatin; sk: https://peptides.cx/sk/library/follistatin; lt: https://peptides.cx/lt/library/follistatin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: FST, FST-344 Category: Muscle / Myostatin Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Research/experimental status. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A myostatin-pathway protein discussed for muscle growth. Human evidence is essentially absent for research-market use. What is it: Follistatin binds and inhibits myostatin and related factors. Proposed mechanisms: - Myostatin inhibition affecting muscle growth Human evidence: Largely experimental (gene-therapy research); research-market peptide use is unvalidated. Animal / preclinical evidence: Muscle-growth effects in models. Safety: Manipulating the myostatin pathway has unknown long-term human risks; unverified material. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy — Journal of Neuromuscular Diseases · PubMed: https://pubmed.ncbi.nlm.nih.gov/27858738/ - Regulation of muscle mass by follistatin and activins — Molecular Endocrinology · PubMed: https://pubmed.ncbi.nlm.nih.gov/20810712/ --- ## SS-31 (Elamipretide) Name: SS-31 (Elamipretide) Canonical URL: https://peptides.cx/library/ss-31 Localized URLs: en: https://peptides.cx/library/ss-31; de: https://peptides.cx/de/library/ss-31; fr: https://peptides.cx/fr/library/ss-31; it: https://peptides.cx/it/library/ss-31; es: https://peptides.cx/es/library/ss-31; el: https://peptides.cx/el/library/ss-31; pl: https://peptides.cx/pl/library/ss-31; nl: https://peptides.cx/nl/library/ss-31; cs: https://peptides.cx/cs/library/ss-31; ro: https://peptides.cx/ro/library/ss-31; bg: https://peptides.cx/bg/library/ss-31; fi: https://peptides.cx/fi/library/ss-31; sv: https://peptides.cx/sv/library/ss-31; sk: https://peptides.cx/sk/library/ss-31; lt: https://peptides.cx/lt/library/ss-31 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Elamipretide, MTP-131 Category: Mitochondrial Evidence grade: B (B — Human, limited) Regulatory status: Investigational; studied in clinical trials. Not an approved general-use medicine. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A mitochondria-targeting peptide studied in clinical trials for mitochondrial disease. What is it: SS-31 is a cell-permeable peptide that targets cardiolipin in mitochondrial membranes. Proposed mechanisms: - Stabilises cardiolipin, supporting mitochondrial function Human evidence: Studied in controlled clinical trials with mixed results; not approved. Animal / preclinical evidence: Protective mitochondrial effects reported. Safety: Investigational; research-market material is not the studied clinical product. Known side effects: - Injection-site reactions reported in trials Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A phase 2/3 randomized clinical trial of elamipretide in Barth syndrome — Genetics in Medicine · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/ - Efficacy and Safety of Elamipretide in Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial — Neurology · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/ --- ## Humanin Name: Humanin Canonical URL: https://peptides.cx/library/humanin Localized URLs: en: https://peptides.cx/library/humanin; de: https://peptides.cx/de/library/humanin; fr: https://peptides.cx/fr/library/humanin; it: https://peptides.cx/it/library/humanin; es: https://peptides.cx/es/library/humanin; el: https://peptides.cx/el/library/humanin; pl: https://peptides.cx/pl/library/humanin; nl: https://peptides.cx/nl/library/humanin; cs: https://peptides.cx/cs/library/humanin; ro: https://peptides.cx/ro/library/humanin; bg: https://peptides.cx/bg/library/humanin; fi: https://peptides.cx/fi/library/humanin; sv: https://peptides.cx/sv/library/humanin; sk: https://peptides.cx/sk/library/humanin; lt: https://peptides.cx/lt/library/humanin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: HN Category: Mitochondrial Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved medicine. Research status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A mitochondrial-derived peptide studied for cytoprotective and metabolic roles. Mostly preclinical. What is it: Humanin is a peptide encoded in mitochondrial DNA with proposed cytoprotective effects. Proposed mechanisms: - Discussed cytoprotective and metabolic signalling Human evidence: Limited; largely observational and mechanistic. Animal / preclinical evidence: Cytoprotective effects reported. Safety: Human safety data is limited; unverified research-market material. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases — Expert Opinion on Therapeutic Targets · PubMed: https://pubmed.ncbi.nlm.nih.gov/30582721/ - Humanin: a harbinger of mitochondrial-derived peptides? — Trends in Endocrinology and Metabolism · PubMed: https://pubmed.ncbi.nlm.nih.gov/23402768/ --- ## Gonadorelin Name: Gonadorelin Canonical URL: https://peptides.cx/library/gonadorelin Localized URLs: en: https://peptides.cx/library/gonadorelin; de: https://peptides.cx/de/library/gonadorelin; fr: https://peptides.cx/fr/library/gonadorelin; it: https://peptides.cx/it/library/gonadorelin; es: https://peptides.cx/es/library/gonadorelin; el: https://peptides.cx/el/library/gonadorelin; pl: https://peptides.cx/pl/library/gonadorelin; nl: https://peptides.cx/nl/library/gonadorelin; cs: https://peptides.cx/cs/library/gonadorelin; ro: https://peptides.cx/ro/library/gonadorelin; bg: https://peptides.cx/bg/library/gonadorelin; fi: https://peptides.cx/fi/library/gonadorelin; sv: https://peptides.cx/sv/library/gonadorelin; sk: https://peptides.cx/sk/library/gonadorelin; lt: https://peptides.cx/lt/library/gonadorelin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: GnRH Category: Endocrine Evidence grade: B (B — Human, limited) Regulatory status: Approved as a medicine for specific endocrine indications in some jurisdictions; prescription-only. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A gonadotropin-releasing hormone used clinically in reproductive endocrinology. What is it: Gonadorelin is synthetic GnRH, central to reproductive hormone regulation. Proposed mechanisms: - Stimulates pituitary LH/FSH release Human evidence: Clinical evidence for approved endocrine uses. Animal / preclinical evidence: Well characterised. Safety: Affects the reproductive hormone axis; appropriate only under medical supervision. Known side effects: - Hormonal effects; context-dependent Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Pulsatile gonadotropin-releasing hormone: clinical applications of a physiologic paradigm — F&S Reports · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC10201297/ - Role of GnRH Stimulation Test in Diagnosing Gonadotropin Deficiency in Delayed Puberty — Chinese Medical Journal · PubMed: https://pubmed.ncbi.nlm.nih.gov/26365959/ --- ## Cerebrolysin Name: Cerebrolysin Canonical URL: https://peptides.cx/library/cerebrolysin Localized URLs: en: https://peptides.cx/library/cerebrolysin; de: https://peptides.cx/de/library/cerebrolysin; fr: https://peptides.cx/fr/library/cerebrolysin; it: https://peptides.cx/it/library/cerebrolysin; es: https://peptides.cx/es/library/cerebrolysin; el: https://peptides.cx/el/library/cerebrolysin; pl: https://peptides.cx/pl/library/cerebrolysin; nl: https://peptides.cx/nl/library/cerebrolysin; cs: https://peptides.cx/cs/library/cerebrolysin; ro: https://peptides.cx/ro/library/cerebrolysin; bg: https://peptides.cx/bg/library/cerebrolysin; fi: https://peptides.cx/fi/library/cerebrolysin; sv: https://peptides.cx/sv/library/cerebrolysin; sk: https://peptides.cx/sk/library/cerebrolysin; lt: https://peptides.cx/lt/library/cerebrolysin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: FPF-1070 Category: Cognitive / Neuro Evidence grade: C (C — Early / Preclinical) Regulatory status: Used as a medicine in some countries; not approved in the US. Prescription where marketed. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A porcine-brain-derived peptide preparation used clinically in some countries for neurological conditions. What is it: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids of neuronal origin. Proposed mechanisms: - Discussed neurotrophic and neuroprotective effects Human evidence: Regional clinical use; independent evidence is mixed. Animal / preclinical evidence: Neurotrophic effects reported. Safety: Where used it is prescribed and monitored; research-market material is unverified. Known side effects: - Injection-site reactions reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Cerebrolysin for acute ischaemic stroke — Cochrane Database of Systematic Reviews · PubMed: https://pubmed.ncbi.nlm.nih.gov/32662068/ - Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve RCTs — Pharmaceuticals (Basel) · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC8708612/ --- ## N-Acetyl Semax Amidate Name: N-Acetyl Semax Amidate Canonical URL: https://peptides.cx/library/n-acetyl-semax Localized URLs: en: https://peptides.cx/library/n-acetyl-semax; de: https://peptides.cx/de/library/n-acetyl-semax; fr: https://peptides.cx/fr/library/n-acetyl-semax; it: https://peptides.cx/it/library/n-acetyl-semax; es: https://peptides.cx/es/library/n-acetyl-semax; el: https://peptides.cx/el/library/n-acetyl-semax; pl: https://peptides.cx/pl/library/n-acetyl-semax; nl: https://peptides.cx/nl/library/n-acetyl-semax; cs: https://peptides.cx/cs/library/n-acetyl-semax; ro: https://peptides.cx/ro/library/n-acetyl-semax; bg: https://peptides.cx/bg/library/n-acetyl-semax; fi: https://peptides.cx/fi/library/n-acetyl-semax; sv: https://peptides.cx/sv/library/n-acetyl-semax; sk: https://peptides.cx/sk/library/n-acetyl-semax; lt: https://peptides.cx/lt/library/n-acetyl-semax Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: NA-Semax, NASA Category: Cognitive Evidence grade: C (C — Early / Preclinical) Regulatory status: Not approved in the EU/US; related to a medicine used in some countries. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A more stable amidated variant of Semax discussed for cognition. Limited independent evidence. What is it: An acetylated, amidated analogue of Semax intended for greater stability. Proposed mechanisms: - Discussed BDNF modulation - Proposed neuroprotective signalling Human evidence: Limited; extrapolated largely from Semax research. Animal / preclinical evidence: Preclinical cognitive effects reported for the Semax family. Safety: Research-market purity is unverified; not a validated therapy. Known side effects: - Nasal irritation with intranasal use reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Source gap: No suitable primary study or review specific to this entry was identified during the last editorial review. --- ## Dihexa Name: Dihexa Canonical URL: https://peptides.cx/library/dihexa Localized URLs: en: https://peptides.cx/library/dihexa; de: https://peptides.cx/de/library/dihexa; fr: https://peptides.cx/fr/library/dihexa; it: https://peptides.cx/it/library/dihexa; es: https://peptides.cx/es/library/dihexa; el: https://peptides.cx/el/library/dihexa; pl: https://peptides.cx/pl/library/dihexa; nl: https://peptides.cx/nl/library/dihexa; cs: https://peptides.cx/cs/library/dihexa; ro: https://peptides.cx/ro/library/dihexa; bg: https://peptides.cx/bg/library/dihexa; fi: https://peptides.cx/fi/library/dihexa; sv: https://peptides.cx/sv/library/dihexa; sk: https://peptides.cx/sk/library/dihexa; lt: https://peptides.cx/lt/library/dihexa Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide Category: Cognitive Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Research chemical status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An experimental peptide discussed for potent effects on synaptic connections. Human data is essentially absent. What is it: Dihexa is an angiotensin-IV-derived compound studied for synaptogenesis. Proposed mechanisms: - Discussed HGF/c-Met pathway effects on synapse formation Human evidence: Essentially none. Animal / preclinical evidence: Preclinical cognitive effects reported. Safety: No human safety data; proliferative pathway involvement warrants caution. Known side effects: - Unknown profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system — Journal of Pharmacology and Experimental Therapeutics · PubMed: https://pubmed.ncbi.nlm.nih.gov/25187433/ - AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway — Brain Sciences · PubMed: https://pubmed.ncbi.nlm.nih.gov/34827486/ --- ## FOXO4-DRI Name: FOXO4-DRI Canonical URL: https://peptides.cx/library/foxo4-dri Localized URLs: en: https://peptides.cx/library/foxo4-dri; de: https://peptides.cx/de/library/foxo4-dri; fr: https://peptides.cx/fr/library/foxo4-dri; it: https://peptides.cx/it/library/foxo4-dri; es: https://peptides.cx/es/library/foxo4-dri; el: https://peptides.cx/el/library/foxo4-dri; pl: https://peptides.cx/pl/library/foxo4-dri; nl: https://peptides.cx/nl/library/foxo4-dri; cs: https://peptides.cx/cs/library/foxo4-dri; ro: https://peptides.cx/ro/library/foxo4-dri; bg: https://peptides.cx/bg/library/foxo4-dri; fi: https://peptides.cx/fi/library/foxo4-dri; sv: https://peptides.cx/sv/library/foxo4-dri; sk: https://peptides.cx/sk/library/foxo4-dri; lt: https://peptides.cx/lt/library/foxo4-dri Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: FOXO4 D-Retro-Inverso Category: Longevity / Senolytic Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Experimental research compound. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An experimental senolytic peptide discussed in longevity circles. Human evidence is absent. What is it: FOXO4-DRI is a designed peptide intended to disrupt a FOXO4–p53 interaction in senescent cells. Proposed mechanisms: - Proposed targeting of senescent cells Human evidence: None; preclinical only. Animal / preclinical evidence: Some senolytic effects reported in mouse studies. Safety: Highly experimental with unknown human safety; unverified material. Known side effects: - Unknown profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging — Cell · PubMed: https://pubmed.ncbi.nlm.nih.gov/28340339/ - Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes — Frontiers in Bioengineering and Biotechnology · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC8116695/ --- ## Adipotide Name: Adipotide Canonical URL: https://peptides.cx/library/adipotide Localized URLs: en: https://peptides.cx/library/adipotide; de: https://peptides.cx/de/library/adipotide; fr: https://peptides.cx/fr/library/adipotide; it: https://peptides.cx/it/library/adipotide; es: https://peptides.cx/es/library/adipotide; el: https://peptides.cx/el/library/adipotide; pl: https://peptides.cx/pl/library/adipotide; nl: https://peptides.cx/nl/library/adipotide; cs: https://peptides.cx/cs/library/adipotide; ro: https://peptides.cx/ro/library/adipotide; bg: https://peptides.cx/bg/library/adipotide; fi: https://peptides.cx/fi/library/adipotide; sv: https://peptides.cx/sv/library/adipotide; sk: https://peptides.cx/sk/library/adipotide; lt: https://peptides.cx/lt/library/adipotide Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: FTPP, Prohibitin-TP01 Category: Metabolic Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Experimental; significant safety concerns. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An experimental fat-loss peptide with serious safety concerns (renal toxicity in studies). Not for human use. What is it: Adipotide is a peptidomimetic targeting the blood supply of fat tissue. Proposed mechanisms: - Targets vasculature of white adipose tissue Human evidence: None established; primate studies showed renal toxicity. Animal / preclinical evidence: Weight loss with nephrotoxicity reported. Safety: Documented kidney toxicity in primate studies. Considered unsafe for human use. Known side effects: - Renal toxicity (in studies) - Dehydration Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys — Science Translational Medicine · PubMed: https://pubmed.ncbi.nlm.nih.gov/22072637/ --- ## Thymalin Name: Thymalin Canonical URL: https://peptides.cx/library/thymalin Localized URLs: en: https://peptides.cx/library/thymalin; de: https://peptides.cx/de/library/thymalin; fr: https://peptides.cx/fr/library/thymalin; it: https://peptides.cx/it/library/thymalin; es: https://peptides.cx/es/library/thymalin; el: https://peptides.cx/el/library/thymalin; pl: https://peptides.cx/pl/library/thymalin; nl: https://peptides.cx/nl/library/thymalin; cs: https://peptides.cx/cs/library/thymalin; ro: https://peptides.cx/ro/library/thymalin; bg: https://peptides.cx/bg/library/thymalin; fi: https://peptides.cx/fi/library/thymalin; sv: https://peptides.cx/sv/library/thymalin; sk: https://peptides.cx/sk/library/thymalin; lt: https://peptides.cx/lt/library/thymalin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Thymus peptide extract Category: Immune Evidence grade: C (C — Early / Preclinical) Regulatory status: Used as a medicine in some countries; not approved in the EU/US. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A thymus-derived peptide preparation discussed for immune modulation. Independent evidence is limited. What is it: Thymalin is a peptide complex derived from the thymus. Proposed mechanisms: - Discussed immune-modulating effects Human evidence: Regional clinical use; limited independent replication. Animal / preclinical evidence: Immune effects reported. Safety: Research-market material is unverified; not a validated therapy where unapproved. Known side effects: - Injection-site reactions reported Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Peptides of pineal gland and thymus prolong human life — Neuro Endocrinology Letters · PubMed: https://pubmed.ncbi.nlm.nih.gov/14523363/ --- ## Pinealon Name: Pinealon Canonical URL: https://peptides.cx/library/pinealon Localized URLs: en: https://peptides.cx/library/pinealon; de: https://peptides.cx/de/library/pinealon; fr: https://peptides.cx/fr/library/pinealon; it: https://peptides.cx/it/library/pinealon; es: https://peptides.cx/es/library/pinealon; el: https://peptides.cx/el/library/pinealon; pl: https://peptides.cx/pl/library/pinealon; nl: https://peptides.cx/nl/library/pinealon; cs: https://peptides.cx/cs/library/pinealon; ro: https://peptides.cx/ro/library/pinealon; bg: https://peptides.cx/bg/library/pinealon; fi: https://peptides.cx/fi/library/pinealon; sv: https://peptides.cx/sv/library/pinealon; sk: https://peptides.cx/sk/library/pinealon; lt: https://peptides.cx/lt/library/pinealon Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: EDR peptide Category: Longevity / Bioregulator Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine. Research status. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A short 'bioregulator' peptide discussed for neuro/longevity effects. Evidence is weak and largely from one research tradition. What is it: Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Russian bioregulator research programme. Proposed mechanisms: - Proposed peptide-bioregulator effects on gene expression Human evidence: Weak; limited independent replication. Animal / preclinical evidence: Some neuroprotective claims from originating groups. Safety: Human safety data is weak; treat claims with caution. Known side effects: - Unknown long-term profile Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes — Rejuvenation Research · PubMed: https://pubmed.ncbi.nlm.nih.gov/21978084/ --- ## Argireline Name: Argireline Canonical URL: https://peptides.cx/library/argireline Localized URLs: en: https://peptides.cx/library/argireline; de: https://peptides.cx/de/library/argireline; fr: https://peptides.cx/fr/library/argireline; it: https://peptides.cx/it/library/argireline; es: https://peptides.cx/es/library/argireline; el: https://peptides.cx/el/library/argireline; pl: https://peptides.cx/pl/library/argireline; nl: https://peptides.cx/nl/library/argireline; cs: https://peptides.cx/cs/library/argireline; ro: https://peptides.cx/ro/library/argireline; bg: https://peptides.cx/bg/library/argireline; fi: https://peptides.cx/fi/library/argireline; sv: https://peptides.cx/sv/library/argireline; sk: https://peptides.cx/sk/library/argireline; lt: https://peptides.cx/lt/library/argireline Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: Acetyl Hexapeptide-8, Acetyl Hexapeptide-3 Category: Skin / Cosmetic Evidence grade: B (B — Human, limited) Regulatory status: Widely used as a topical cosmetic ingredient. Cosmetic use is broadly permitted. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A popular topical cosmetic peptide marketed for the appearance of expression lines. Topical, not injected. What is it: Argireline is a synthetic peptide used in anti-ageing cosmetic formulations. Proposed mechanisms: - Discussed topical effects on neurotransmitter release at the skin surface Human evidence: Cosmetic studies report modest improvements in the appearance of fine lines. Animal / preclinical evidence: Not the primary evidence base; mechanistic/in-vitro data exists. Safety: Generally well tolerated topically. This is a cosmetic ingredient, not an injectable. Known side effects: - Mild topical irritation in some users Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — American Journal of Clinical Dermatology · PubMed: https://pubmed.ncbi.nlm.nih.gov/23417317/ - Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy — International Journal of Molecular Sciences · PubMed: https://pubmed.ncbi.nlm.nih.gov/40565185/ --- ## Matrixyl Name: Matrixyl Canonical URL: https://peptides.cx/library/matrixyl Localized URLs: en: https://peptides.cx/library/matrixyl; de: https://peptides.cx/de/library/matrixyl; fr: https://peptides.cx/fr/library/matrixyl; it: https://peptides.cx/it/library/matrixyl; es: https://peptides.cx/es/library/matrixyl; el: https://peptides.cx/el/library/matrixyl; pl: https://peptides.cx/pl/library/matrixyl; nl: https://peptides.cx/nl/library/matrixyl; cs: https://peptides.cx/cs/library/matrixyl; ro: https://peptides.cx/ro/library/matrixyl; bg: https://peptides.cx/bg/library/matrixyl; fi: https://peptides.cx/fi/library/matrixyl; sv: https://peptides.cx/sv/library/matrixyl; sk: https://peptides.cx/sk/library/matrixyl; lt: https://peptides.cx/lt/library/matrixyl Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: None verified Offer last checked: No peptide-specific offer Also known as: Palmitoyl Pentapeptide-4, Pal-KTTKS Category: Skin / Cosmetic Evidence grade: B (B — Human, limited) Regulatory status: Widely used as a topical cosmetic ingredient. Cosmetic use is broadly permitted. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A well-known topical cosmetic peptide marketed for skin firmness and fine lines. What is it: Matrixyl is a palmitoylated peptide used in topical skincare to support collagen-related pathways. Proposed mechanisms: - Discussed stimulation of extracellular-matrix components in skin Human evidence: Cosmetic studies report improvements in skin appearance. Animal / preclinical evidence: Mechanistic/in-vitro support. Safety: Generally well tolerated topically; a cosmetic ingredient, not an injectable. Known side effects: - Rare topical irritation Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin — International Journal of Cosmetic Science · PubMed: https://pubmed.ncbi.nlm.nih.gov/18492182/ - Double-blind, Randomized Trial on Acetylhexapeptide-3 and Palmitoyl Pentapeptide-4 Cream for Crow's Feet — Journal of Clinical and Aesthetic Dermatology · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC10005804/ --- ## SNAP-8 Name: SNAP-8 Canonical URL: https://peptides.cx/library/snap-8 Localized URLs: en: https://peptides.cx/library/snap-8; de: https://peptides.cx/de/library/snap-8; fr: https://peptides.cx/fr/library/snap-8; it: https://peptides.cx/it/library/snap-8; es: https://peptides.cx/es/library/snap-8; el: https://peptides.cx/el/library/snap-8; pl: https://peptides.cx/pl/library/snap-8; nl: https://peptides.cx/nl/library/snap-8; cs: https://peptides.cx/cs/library/snap-8; ro: https://peptides.cx/ro/library/snap-8; bg: https://peptides.cx/bg/library/snap-8; fi: https://peptides.cx/fi/library/snap-8; sv: https://peptides.cx/sv/library/snap-8; sk: https://peptides.cx/sk/library/snap-8; lt: https://peptides.cx/lt/library/snap-8 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Acetyl Octapeptide-3 Category: Skin / Cosmetic Evidence grade: C (C — Early / Preclinical) Regulatory status: Used as a topical cosmetic ingredient. Cosmetic use is broadly permitted. Risk flag: no Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A topical cosmetic peptide, an extension of the Argireline concept, marketed for expression lines. What is it: SNAP-8 is an octapeptide used in anti-ageing cosmetics. Proposed mechanisms: - Discussed topical effects on expression-line appearance Human evidence: Limited cosmetic data. Animal / preclinical evidence: Mechanistic/in-vitro data. Safety: Topical cosmetic ingredient; generally well tolerated. Known side effects: - Mild topical irritation in some users Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy — Frontiers in Chemistry · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC7662462/ --- ## VIP Name: VIP Canonical URL: https://peptides.cx/library/vip Localized URLs: en: https://peptides.cx/library/vip; de: https://peptides.cx/de/library/vip; fr: https://peptides.cx/fr/library/vip; it: https://peptides.cx/it/library/vip; es: https://peptides.cx/es/library/vip; el: https://peptides.cx/el/library/vip; pl: https://peptides.cx/pl/library/vip; nl: https://peptides.cx/nl/library/vip; cs: https://peptides.cx/cs/library/vip; ro: https://peptides.cx/ro/library/vip; bg: https://peptides.cx/bg/library/vip; fi: https://peptides.cx/fi/library/vip; sv: https://peptides.cx/sv/library/vip; sk: https://peptides.cx/sk/library/vip; lt: https://peptides.cx/lt/library/vip Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Vasoactive Intestinal Peptide Category: Immune / Neuro Evidence grade: C (C — Early / Preclinical) Regulatory status: Not an approved general-use medicine; used in specific medical/diagnostic contexts. Risk flag: yes Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A signalling peptide discussed in niche protocols. Affects vasculature and immune signalling; not a casual compound. What is it: VIP is an endogenous peptide with roles in vasodilation and immune/neural signalling. Proposed mechanisms: - Vasodilation - Immune and neuroendocrine signalling Human evidence: Limited outside specific medical contexts. Animal / preclinical evidence: Well characterised physiologically. Safety: Can affect blood pressure; appropriate only under medical supervision. Known side effects: - Flushing - Blood-pressure effects Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: a 60-Day RCT — Critical Care Medicine · PubMed: https://pubmed.ncbi.nlm.nih.gov/36044317/ - Intravenous aviptadil and remdesivir for COVID-19-associated hypoxaemic respiratory failure (TESICO): a randomised, placebo-controlled trial — Lancet Respiratory Medicine · PubMed: https://pubmed.ncbi.nlm.nih.gov/37348524/ --- ## Cagrilintide Name: Cagrilintide Canonical URL: https://peptides.cx/library/cagrilintide Localized URLs: en: https://peptides.cx/library/cagrilintide; de: https://peptides.cx/de/library/cagrilintide; fr: https://peptides.cx/fr/library/cagrilintide; it: https://peptides.cx/it/library/cagrilintide; es: https://peptides.cx/es/library/cagrilintide; el: https://peptides.cx/el/library/cagrilintide; pl: https://peptides.cx/pl/library/cagrilintide; nl: https://peptides.cx/nl/library/cagrilintide; cs: https://peptides.cx/cs/library/cagrilintide; ro: https://peptides.cx/ro/library/cagrilintide; bg: https://peptides.cx/bg/library/cagrilintide; fi: https://peptides.cx/fi/library/cagrilintide; sv: https://peptides.cx/sv/library/cagrilintide; sk: https://peptides.cx/sk/library/cagrilintide; lt: https://peptides.cx/lt/library/cagrilintide Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: AM833, NNC0174-0833, long-acting amylin analogue Category: Metabolic Evidence grade: B (B — Human, limited) Regulatory status: Investigational; not an approved medicine in the EU or US as of mid-2026. Developed by Novo Nordisk; the fixed combination with semaglutide (CagriSema) is under regulatory review. Investigational product, not a general-use compound. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A long-acting amylin analogue studied for weight management, mostly in combination with semaglutide. Human trial data are substantial but it is not yet approved anywhere. What is it: Cagrilintide is a long-acting synthetic analogue of amylin, a pancreatic hormone co-secreted with insulin that influences satiety and gastric emptying. It is being developed by Novo Nordisk for chronic weight management, primarily as a once-weekly combination with semaglutide known as CagriSema. It is an investigational drug, not an approved medicine. Proposed mechanisms: - Agonism of amylin and calcitonin receptors, a well-characterised satiety-signalling pathway - Proposed slowing of gastric emptying and reduction of food intake - Discussed as complementary to GLP-1 receptor agonism when combined with semaglutide Human evidence: A randomised phase 2 dose-finding trial (Lancet, 2021) reported dose-dependent weight reduction with cagrilintide monotherapy in people with overweight or obesity. The phase 3 REDEFINE 1 trial (NEJM, 2025) tested it combined with semaglutide and found clinically meaningful weight loss versus placebo. Cagrilintide alone is not approved, and long-term outcomes and safety of monotherapy are not established. Animal / preclinical evidence: Characterised in preclinical obesity models, where amylin-receptor agonism reduced food intake and body weight. Safety: Across trials the most common adverse events were gastrointestinal (nausea, constipation, diarrhoea) and injection-site reactions. As an investigational product its full long-term safety profile is not established, and research-market material is not a quality-assured or pharmacist-dispensed medicine. Known side effects: - Nausea - Constipation - Diarrhoea - Injection-site reactions Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Once-weekly cagrilintide for weight management in people with overweight and obesity: a randomised, dose-finding phase 2 trial — The Lancet · PubMed: https://pubmed.ncbi.nlm.nih.gov/34798060/ - Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) — New England Journal of Medicine · PubMed: https://pubmed.ncbi.nlm.nih.gov/40544433/ --- ## ARA-290 Name: ARA-290 Canonical URL: https://peptides.cx/library/ara-290 Localized URLs: en: https://peptides.cx/library/ara-290; de: https://peptides.cx/de/library/ara-290; fr: https://peptides.cx/fr/library/ara-290; it: https://peptides.cx/it/library/ara-290; es: https://peptides.cx/es/library/ara-290; el: https://peptides.cx/el/library/ara-290; pl: https://peptides.cx/pl/library/ara-290; nl: https://peptides.cx/nl/library/ara-290; cs: https://peptides.cx/cs/library/ara-290; ro: https://peptides.cx/ro/library/ara-290; bg: https://peptides.cx/bg/library/ara-290; fi: https://peptides.cx/fi/library/ara-290; sv: https://peptides.cx/sv/library/ara-290; sk: https://peptides.cx/sk/library/ara-290; lt: https://peptides.cx/lt/library/ara-290 Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Cibinetide, pHBSP, innate repair receptor agonist Category: Immune Evidence grade: C (C — Early / Preclinical) Regulatory status: Not approved by the FDA, EMA, or any major regulator for any indication. It received orphan-drug and fast-track designations for sarcoidosis, but these are development incentives, not approvals. Clinical development stalled after phase 2; sold only as a research chemical, not authorised for human use. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An erythropoietin-derived peptide studied for small-fibre neuropathy in sarcoidosis. Human data come from small phase 2 trials with surrogate endpoints; it is not approved and development has stalled. What is it: ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from a region of the erythropoietin (EPO) molecule. It was designed to activate tissue-protective signalling without the red-blood-cell-stimulating effects of EPO. It is an investigational compound that has not completed clinical development. Proposed mechanisms: - Proposed agonism of the 'innate repair receptor' (an EPO-receptor/CD131 heterocomplex) - Discussed anti-inflammatory and tissue-protective signalling - Proposed support of small-nerve-fibre regeneration in neuropathy Human evidence: Two small randomised, placebo-controlled phase 2 trials in sarcoidosis-associated small-fibre neuropathy (Molecular Medicine, 2013; Investigative Ophthalmology & Visual Science, 2017) reported improvements in corneal nerve-fibre measures and neuropathic symptoms over 28 days. These studies were small, short, and relied on surrogate endpoints; no phase 3 confirmation exists and outcomes for other conditions are unproven. Animal / preclinical evidence: Preclinical models of neuropathy, ischaemia, and inflammation reported tissue-protective and anti-inflammatory effects, which motivated the human trials. Safety: In the short phase 2 trials it was generally well tolerated with no serious adverse events reported, but these involved few participants over about four weeks. Long-term safety is unknown, and it is not a licensed medicine or quality-assured product. Known side effects: - Injection-site reactions - Limited safety data from small, short trials Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density — Molecular Medicine · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/ - Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Investigative Ophthalmology & Visual Science · PubMed: https://pubmed.ncbi.nlm.nih.gov/28475703/ --- ## Oxytocin Name: Oxytocin Canonical URL: https://peptides.cx/library/oxytocin Localized URLs: en: https://peptides.cx/library/oxytocin; de: https://peptides.cx/de/library/oxytocin; fr: https://peptides.cx/fr/library/oxytocin; it: https://peptides.cx/it/library/oxytocin; es: https://peptides.cx/es/library/oxytocin; el: https://peptides.cx/el/library/oxytocin; pl: https://peptides.cx/pl/library/oxytocin; nl: https://peptides.cx/nl/library/oxytocin; cs: https://peptides.cx/cs/library/oxytocin; ro: https://peptides.cx/ro/library/oxytocin; bg: https://peptides.cx/bg/library/oxytocin; fi: https://peptides.cx/fi/library/oxytocin; sv: https://peptides.cx/sv/library/oxytocin; sk: https://peptides.cx/sk/library/oxytocin; lt: https://peptides.cx/lt/library/oxytocin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Pitocin, Syntocinon, OT Category: Endocrine Evidence grade: A (A — Approved / Strong) Regulatory status: An approved prescription medicine in the EU and US for obstetric use — induction or augmentation of labour and control of postpartum bleeding — administered under medical supervision. The widely discussed intranasal and behavioural uses are not approved and remain investigational. Prescription-only. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A hormone approved as an injectable obstetric medicine. Its popular 'bonding' and social-cognition uses are intranasal and unapproved, with inconsistent trial evidence. What is it: Oxytocin is a nine-amino-acid peptide hormone produced in the hypothalamus and released by the posterior pituitary, and it is also manufactured synthetically. As a licensed drug it is used intravenously or intramuscularly in obstetric care. Separately, an intranasal form is used only in research into social and psychiatric effects. Proposed mechanisms: - Oxytocin-receptor agonism causing uterine smooth-muscle contraction and milk let-down - Central nervous system signalling discussed in relation to social and affiliative behaviour Human evidence: Efficacy is well established and approved for its obstetric indications. For the popular behavioural uses — intranasal oxytocin for autism, trust, or social cognition — the evidence is inconsistent: a meta-analysis of randomised trials (Psychoneuroendocrinology, 2018) found at most small effects and largely inconclusive results, limited by small samples and heterogeneity. Animal / preclinical evidence: Extensively studied in animal models of pair-bonding, maternal behaviour, and social affiliation. Safety: Intravenous obstetric use carries significant risks, including uterine hyperstimulation, water intoxication with hyponatraemia, and adverse fetal effects, and is only appropriate under medical supervision. Intranasal research doses are generally reported to cause mild, transient effects, but that form is not a licensed product. Known side effects: - Uterine hyperstimulation (obstetric IV use) - Water intoxication / hyponatraemia - Nausea - Headache or nasal irritation (intranasal use) Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - PITOCIN (oxytocin injection, USP) — Prescribing Information — U.S. FDA · DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=969d5b35-0add-4c23-9605-6a5b6ab65c95 - Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis — Psychoneuroendocrinology · PubMed: https://pubmed.ncbi.nlm.nih.gov/29032324/ --- ## HCG Name: HCG Canonical URL: https://peptides.cx/library/hcg Localized URLs: en: https://peptides.cx/library/hcg; de: https://peptides.cx/de/library/hcg; fr: https://peptides.cx/fr/library/hcg; it: https://peptides.cx/it/library/hcg; es: https://peptides.cx/es/library/hcg; el: https://peptides.cx/el/library/hcg; pl: https://peptides.cx/pl/library/hcg; nl: https://peptides.cx/nl/library/hcg; cs: https://peptides.cx/cs/library/hcg; ro: https://peptides.cx/ro/library/hcg; bg: https://peptides.cx/bg/library/hcg; fi: https://peptides.cx/fi/library/hcg; sv: https://peptides.cx/sv/library/hcg; sk: https://peptides.cx/sk/library/hcg; lt: https://peptides.cx/lt/library/hcg Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Human chorionic gonadotropin, Pregnyl, Novarel, choriogonadotropin Category: Endocrine Evidence grade: A (A — Approved / Strong) Regulatory status: An approved prescription medicine in the EU and US for prepubertal cryptorchidism, selected cases of male hypogonadotropic hypogonadism, and induction of ovulation in women pretreated with menotropins. The FDA-approved label explicitly states it is not effective for weight loss or obesity. Prescription-only. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A placental hormone approved as a prescription drug for specific fertility and endocrine uses. Its labelled uses are well established; the 'hCG diet' is explicitly unsupported by the drug's own labelling. What is it: Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by the placenta during pregnancy, and it acts on the same receptor as luteinising hormone (LH). Manufactured urinary-derived and recombinant forms are approved prescription drugs used in fertility and endocrine medicine. Proposed mechanisms: - LH-receptor agonism stimulating testicular Leydig-cell testosterone production and testicular descent - Triggering of ovulation in women as part of assisted-reproduction protocols Human evidence: Evidence supports its approved endocrine and fertility indications. Off-label use in men for hypogonadism or fertility preservation has supportive but limited data from mostly small studies. Use for weight loss is not supported: the approved label states there is no substantial evidence it aids weight loss and that it has no known effect on fat mobilisation, appetite, or fat distribution. Animal / preclinical evidence: Gonadotropic effects on the testis and ovary are well characterised across species. Safety: A prescription hormone requiring medical supervision. Reported risks include ovarian hyperstimulation syndrome in women, thromboembolism, precocious puberty in treated children, and gynaecomastia in men. Non-medical or 'diet' use is unsupervised and carries these risks without benefit. Known side effects: - Injection-site pain - Headache, irritability, or mood changes - Oedema - Ovarian hyperstimulation (women) / gynaecomastia (men) Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - PREGNYL (chorionic gonadotropin for injection, USP) — Prescribing Information — U.S. FDA · DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc604794-6dd6-43a7-85fa-2f04ed325c33 - Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men — Translational Andrology and Urology · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC6087849/ --- ## HGH Name: HGH Canonical URL: https://peptides.cx/library/hgh Localized URLs: en: https://peptides.cx/library/hgh; de: https://peptides.cx/de/library/hgh; fr: https://peptides.cx/fr/library/hgh; it: https://peptides.cx/it/library/hgh; es: https://peptides.cx/es/library/hgh; el: https://peptides.cx/el/library/hgh; pl: https://peptides.cx/pl/library/hgh; nl: https://peptides.cx/nl/library/hgh; cs: https://peptides.cx/cs/library/hgh; ro: https://peptides.cx/ro/library/hgh; bg: https://peptides.cx/bg/library/hgh; fi: https://peptides.cx/fi/library/hgh; sv: https://peptides.cx/sv/library/hgh; sk: https://peptides.cx/sk/library/hgh; lt: https://peptides.cx/lt/library/hgh Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Somatropin, Human growth hormone, Genotropin, Norditropin, GH Category: Growth Hormone Secretagogue Evidence grade: A (A — Approved / Strong) Regulatory status: An approved prescription medicine (somatropin) in the EU and US for defined growth-hormone-deficiency and growth disorders in children and adults. In the US, distributing HGH for non-approved uses such as anti-ageing or athletic enhancement is specifically prohibited by federal law (21 U.S.C. §333(e)). Prescription-only. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: Recombinant growth hormone, approved for genuine GH deficiency and specific growth disorders. Anti-ageing and body-composition use in healthy adults is not supported and is legally restricted in the US. What is it: Somatropin is recombinant human growth hormone (HGH), a 191-amino-acid protein identical to the growth hormone made by the pituitary gland. It is an approved prescription drug used to replace deficient growth hormone or treat certain growth disorders under medical supervision. Proposed mechanisms: - Growth-hormone-receptor agonism driving hepatic and peripheral IGF-1 production - Promotion of linear growth, lipolysis, and protein anabolism - Effects on glucose and insulin metabolism Human evidence: Strong clinical evidence and regulatory approval support its use in genuine growth-hormone deficiency and defined paediatric growth disorders. For anti-ageing or body-composition use in healthy adults, a systematic review (Annals of Internal Medicine, 2007) found only small body-composition changes offset by higher rates of adverse events, and concluded it cannot be recommended as an anti-ageing therapy. Animal / preclinical evidence: Growth, metabolic, and IGF-1-axis effects are extensively characterised across species. Safety: A prescription hormone with significant risks, including fluid retention, joint and muscle pain, carpal tunnel syndrome, and insulin resistance or impaired glucose tolerance. It is contraindicated in acute critical illness and active malignancy, with an increased-mortality signal in critically ill patients. Non-medical use is unsafe and, in the US, unlawful. Known side effects: - Fluid retention / oedema - Joint and muscle pain - Carpal tunnel syndrome - Insulin resistance / raised blood glucose Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - GENOTROPIN (somatropin) for injection — Prescribing Information — U.S. FDA · DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765 - Systematic review: the safety and efficacy of growth hormone in the healthy elderly — Annals of Internal Medicine · PubMed: https://pubmed.ncbi.nlm.nih.gov/17227934/ - 21 U.S. Code §333(e) — prohibited distribution of human growth hormone — Cornell Law School Legal Information Institute: https://www.law.cornell.edu/uscode/text/21/333 --- ## Adamax Name: Adamax Canonical URL: https://peptides.cx/library/adamax Localized URLs: en: https://peptides.cx/library/adamax; de: https://peptides.cx/de/library/adamax; fr: https://peptides.cx/fr/library/adamax; it: https://peptides.cx/it/library/adamax; es: https://peptides.cx/es/library/adamax; el: https://peptides.cx/el/library/adamax; pl: https://peptides.cx/pl/library/adamax; nl: https://peptides.cx/nl/library/adamax; cs: https://peptides.cx/cs/library/adamax; ro: https://peptides.cx/ro/library/adamax; bg: https://peptides.cx/bg/library/adamax; fi: https://peptides.cx/fi/library/adamax; sv: https://peptides.cx/sv/library/adamax; sk: https://peptides.cx/sk/library/adamax; lt: https://peptides.cx/lt/library/adamax Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Adamax peptide, Semax/ACTH-fragment analogue (vendor description) Category: Cognitive Evidence grade: D (D — Anecdotal) Regulatory status: Not approved for human use in any jurisdiction. Sold as a 'research chemical.' New Zealand's Medsafe recorded it in border seizures and, in a June 2025 submission, proposed classifying ACTH-analogue nootropic peptides (naming Adamax and Semax) as prescription medicines. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A research-market nootropic peptide marketed as a modified analogue of Semax. There is no peer-reviewed pharmacology on Adamax itself, and even its chemical identity is inconsistently described; claims about it are anecdotal. What is it: Adamax is a research-chemical peptide sold as a nootropic and described by vendors as a modified analogue of Semax (itself an ACTH-derived peptide). Its exact structure is not consistently defined across sources, and no peer-reviewed study characterising this specific compound has been published. Regulators have encountered it as an unapproved product in border seizures. Proposed mechanisms: - Marketed as a Semax-type/ACTH-fragment analogue, but this has not been demonstrated for Adamax in any published study - Vendor materials claim greater blood-brain-barrier penetration or increased BDNF, none supported by peer-reviewed data on this compound - The proposed structure differs between sources, so even the identity of Adamax is uncertain Human evidence: There is no peer-reviewed human research on Adamax. No clinical trials, pharmacokinetic studies, or controlled cognitive-outcome data exist. Reported effects come from vendor pages and user forums only. Animal / preclinical evidence: No peer-reviewed animal studies of Adamax specifically could be located. Related peptides such as Semax have their own literature, but those findings cannot be assumed to transfer to a differently modified, poorly characterised compound. Safety: The safety profile of Adamax is unknown. Because it is unapproved and its composition, purity, and pharmacology are not established, its potential adverse effects and interactions cannot be characterised. Known side effects: - No adverse-effect profile has been established in humans; nothing is documented in peer-reviewed literature Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Classification of Unscheduled Peptides — Submission to the Medicines Classification Committee (June 2025) — Medsafe — New Zealand Medicines and Medical Devices Safety Authority: https://www.medsafe.govt.nz/profs/class/Agendas/Agen74/5.7Peptides.pdf --- ## Cartalax Name: Cartalax Canonical URL: https://peptides.cx/library/cartalax Localized URLs: en: https://peptides.cx/library/cartalax; de: https://peptides.cx/de/library/cartalax; fr: https://peptides.cx/fr/library/cartalax; it: https://peptides.cx/it/library/cartalax; es: https://peptides.cx/es/library/cartalax; el: https://peptides.cx/el/library/cartalax; pl: https://peptides.cx/pl/library/cartalax; nl: https://peptides.cx/nl/library/cartalax; cs: https://peptides.cx/cs/library/cartalax; ro: https://peptides.cx/ro/library/cartalax; bg: https://peptides.cx/bg/library/cartalax; fi: https://peptides.cx/fi/library/cartalax; sv: https://peptides.cx/sv/library/cartalax; sk: https://peptides.cx/sk/library/cartalax; lt: https://peptides.cx/lt/library/cartalax Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Ala-Glu-Asp, AED, AED peptide Category: Recovery / Regeneration Evidence grade: C (C — Early / Preclinical) Regulatory status: Not approved as a drug in any jurisdiction (no FDA, EMA, or comparable marketing authorisation). Sold as a 'research chemical' / peptide bioregulator. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A synthetic Khavinson-type tripeptide (Ala-Glu-Asp) marketed for cartilage and connective-tissue support. Published data are limited to in vitro and mechanistic work from a single research tradition; there are no clinical trials, and the marketed joint/cartilage use is essentially unsupported. What is it: Cartalax is a synthetic short peptide with the sequence Ala-Glu-Asp (AED), one of the 'peptide bioregulators' associated with the research group led by Vladimir Khavinson. It is sold on the research-chemical market for cartilage and connective-tissue applications and is not an approved drug in any jurisdiction. Proposed mechanisms: - Proposed to act as a peptide bioregulator affecting gene expression; in vitro work reports the AED peptide can influence differentiation of cultured human stem cells - Khavinson-group publications hypothesise such short peptides interact with DNA/chromatin to modulate transcription, but this remains a hypothesis - A specific, validated mechanism in cartilage or chondrocytes has not been demonstrated in peer-reviewed literature Human evidence: There are no controlled human trials of Cartalax. The peer-reviewed work on the AED peptide is in vitro and comes largely from one research group. No published clinical evidence supports the marketed cartilage or joint-repair claims. Animal / preclinical evidence: Direct, independently replicated animal efficacy studies of Cartalax for cartilage are scarce to absent in the indexed literature; most supporting material is mechanistic or review-level rather than controlled in vivo data. Safety: Human safety data are lacking. As an unapproved peptide sold for research use, its purity, long-term effects, and interactions are not established. Known side effects: - No adverse-effect profile has been characterised in humans; controlled safety data are absent Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Effect of short peptides on neuronal differentiation of stem cells — International Journal of Immunopathology and Pharmacology · PubMed: https://pubmed.ncbi.nlm.nih.gov/30791821/ - Peptide Regulation of Gene Expression: A Systematic Review — Molecules · PubMed: https://pubmed.ncbi.nlm.nih.gov/34834147/ --- ## AHK-Cu Name: AHK-Cu Canonical URL: https://peptides.cx/library/ahk-cu Localized URLs: en: https://peptides.cx/library/ahk-cu; de: https://peptides.cx/de/library/ahk-cu; fr: https://peptides.cx/fr/library/ahk-cu; it: https://peptides.cx/it/library/ahk-cu; es: https://peptides.cx/es/library/ahk-cu; el: https://peptides.cx/el/library/ahk-cu; pl: https://peptides.cx/pl/library/ahk-cu; nl: https://peptides.cx/nl/library/ahk-cu; cs: https://peptides.cx/cs/library/ahk-cu; ro: https://peptides.cx/ro/library/ahk-cu; bg: https://peptides.cx/bg/library/ahk-cu; fi: https://peptides.cx/fi/library/ahk-cu; sv: https://peptides.cx/sv/library/ahk-cu; sk: https://peptides.cx/sk/library/ahk-cu; lt: https://peptides.cx/lt/library/ahk-cu Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Copper Tripeptide-3, AHK copper peptide, alanyl-histidyl-lysine copper, Ala-His-Lys-Cu Category: Skin / Cosmetic Evidence grade: C (C — Early / Preclinical) Regulatory status: Not approved as a drug. The tripeptide appears as a cosmetic ingredient (INCI 'Copper Tripeptide-3') in topical products; injectable or systemic use is unapproved and sold only as a 'research chemical.' Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A copper-binding tripeptide (alanine-histidine-lysine plus copper) marketed for hair growth and skin. Evidence is limited to a small amount of in vitro/ex vivo laboratory work; robust human clinical data are lacking. What is it: AHK-Cu is a copper complex of the tripeptide alanyl-histidyl-lysine, also sold cosmetically as 'Copper Tripeptide-3.' It is a chemical sibling of the better-known copper peptide GHK-Cu and is marketed for hair-follicle stimulation and skin support. It appears mainly as a cosmetic ingredient or a 'research chemical' rather than an approved medicine. Proposed mechanisms: - In an in vitro/ex vivo study, AHK-Cu was reported to promote elongation of cultured human hair follicles and proliferation of dermal papilla cells - Proposed effects include supporting dermal papilla cell survival and increasing VEGF, consistent with copper-peptide biology, though this rests on limited data - As a copper carrier it is discussed alongside GHK-Cu, but has far less published research of its own Human evidence: Human clinical evidence for AHK-Cu is very limited. The most-cited study used cultured human cells and excised follicles (in vitro/ex vivo), not living participants. Well-controlled clinical trials specifically on AHK-Cu are lacking, and some efficacy figures circulating online are not supported by locatable peer-reviewed trials. Animal / preclinical evidence: Dedicated animal-model data for AHK-Cu are sparse in the indexed literature; most mechanistic support comes from cell-culture and ex vivo tissue work. Safety: Topical copper peptides are generally regarded as well tolerated in cosmetic use, but AHK-Cu itself has limited safety documentation, and there is little human data for injectable or systemic use. Local skin reactions are plausible with topical application. Known side effects: - Possible local skin irritation or redness with topical use - For injectable or systemic use, the adverse-effect profile is not established in humans Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - The effect of tripeptide-copper complex on human hair growth in vitro — Archives of Pharmacal Research · PubMed: https://pubmed.ncbi.nlm.nih.gov/17703734/ --- ## 5-Amino-1MQ Name: 5-Amino-1MQ Canonical URL: https://peptides.cx/library/5-amino-1mq Localized URLs: en: https://peptides.cx/library/5-amino-1mq; de: https://peptides.cx/de/library/5-amino-1mq; fr: https://peptides.cx/fr/library/5-amino-1mq; it: https://peptides.cx/it/library/5-amino-1mq; es: https://peptides.cx/es/library/5-amino-1mq; el: https://peptides.cx/el/library/5-amino-1mq; pl: https://peptides.cx/pl/library/5-amino-1mq; nl: https://peptides.cx/nl/library/5-amino-1mq; cs: https://peptides.cx/cs/library/5-amino-1mq; ro: https://peptides.cx/ro/library/5-amino-1mq; bg: https://peptides.cx/bg/library/5-amino-1mq; fi: https://peptides.cx/fi/library/5-amino-1mq; sv: https://peptides.cx/sv/library/5-amino-1mq; sk: https://peptides.cx/sk/library/5-amino-1mq; lt: https://peptides.cx/lt/library/5-amino-1mq Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: 5-amino-1-methylquinolinium, 5A1MQ, NNMT inhibitor Category: Metabolic Evidence grade: C (C — Early / Preclinical) Regulatory status: Not approved for human use in any jurisdiction and not a recognised dietary supplement. A small molecule, not a peptide. Sold only as a 'research chemical.' Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A small-molecule NNMT inhibitor — not a peptide — investigated for fat metabolism and weight. Evidence is preclinical only, from cell and rodent studies, with no published human trials. What is it: 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is not a peptide, despite frequently being sold alongside peptides. It is marketed for weight loss and metabolic support and is not approved for human use. Proposed mechanisms: - Inhibits NNMT, an enzyme in NAD+/methylation metabolism reported to be elevated in obese adipose tissue - In preclinical models, NNMT inhibition is associated with reduced fat-cell size and body weight, proposed to work by shifting cellular energy metabolism - These mechanisms come from animal and cell studies; whether they translate to humans is unknown Human evidence: There are no published human clinical trials of 5-Amino-1MQ. No peer-reviewed human efficacy or safety data exist; all controlled evidence is from rodents and cell culture. Animal / preclinical evidence: In diet-induced obese mice, a lead NNMT inhibitor (5-amino-1MQ) reduced body weight and white-adipose mass and lowered plasma cholesterol without changing food intake in that study. The findings are preclinical and have not been confirmed in humans. Safety: Human safety is unknown. Because it is unapproved and untested in people, its adverse-effect profile, long-term risks, and drug interactions are not established. Known side effects: - No human adverse-effect profile has been established; safety observations come only from short-term animal studies Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — Biochemical Pharmacology · PubMed: https://pubmed.ncbi.nlm.nih.gov/29155147/ - Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes — BioMed Research International · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/ --- ## AICAR Name: AICAR Canonical URL: https://peptides.cx/library/aicar Localized URLs: en: https://peptides.cx/library/aicar; de: https://peptides.cx/de/library/aicar; fr: https://peptides.cx/fr/library/aicar; it: https://peptides.cx/it/library/aicar; es: https://peptides.cx/es/library/aicar; el: https://peptides.cx/el/library/aicar; pl: https://peptides.cx/pl/library/aicar; nl: https://peptides.cx/nl/library/aicar; cs: https://peptides.cx/cs/library/aicar; ro: https://peptides.cx/ro/library/aicar; bg: https://peptides.cx/bg/library/aicar; fi: https://peptides.cx/fi/library/aicar; sv: https://peptides.cx/sv/library/aicar; sk: https://peptides.cx/sk/library/aicar; lt: https://peptides.cx/lt/library/aicar Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: Acadesine, AICA riboside, 5-aminoimidazole-4-carboxamide ribonucleoside Category: Metabolic Evidence grade: B (B — Human, limited) Regulatory status: A small-molecule AMPK activator, not a peptide. Not approved for human use in any jurisdiction (development as acadesine was discontinued). Prohibited at all times in sport by WADA as an S4 hormone and metabolic modulator. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An AMPK-activating small molecule (AICA ribonucleoside / acadesine), not a peptide, marketed as an 'exercise mimetic.' It went through large human cardiac-surgery trials that showed no benefit, is not approved anywhere, and is banned in sport by WADA. What is it: AICAR (5-aminoimidazole-4-carboxamide ribonucleoside), also called acadesine, is a small-molecule AMP analogue that activates AMP-activated protein kinase (AMPK). It is not a peptide. It is sold on the research-chemical market as an endurance / 'exercise-mimetic' and fat-loss agent, is unapproved for human use, and is on the WADA Prohibited List. Proposed mechanisms: - Converted inside cells to ZMP, an AMP mimetic that activates AMPK, a cellular energy sensor - AMPK activation is reported to increase fatty-acid oxidation, glucose uptake, and mitochondrial biogenesis, which underlies the 'exercise-mimetic' marketing - A systematic review cautions that many AICAR effects are in fact AMPK-independent, so its pharmacology is less clean than often presented Human evidence: AICAR (as acadesine) has been studied in large human trials — but for cardioprotection during coronary artery bypass surgery, not fitness. The pivotal RED-CABG randomised trial (~3,000 patients) was stopped for futility and showed no benefit. No human evidence supports its marketed performance or fat-loss uses, and it has never been approved. Animal / preclinical evidence: Rodent studies popularised AICAR as an 'exercise mimetic,' reporting increased endurance and metabolic changes. These animal findings drove interest but did not translate into demonstrated human benefit. Safety: AICAR is unapproved for human use and prohibited in sport. In cardiac-surgery trials it was tolerated short-term under medical supervision, but higher-dose studies raised concerns such as kidney toxicity. Long-term safety outside a trial setting is not established. Known side effects: - Kidney toxicity reported in high-dose clinical studies - Anti-doping authorities note potential risks from excessive or inappropriate AMPK activation - The full adverse-effect profile for non-medical use is not established Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Effect of the Adenosine-Regulating Agent Acadesine on Morbidity and Mortality Associated With CABG: The RED-CABG Randomized Controlled Trial — JAMA · PubMed: https://pubmed.ncbi.nlm.nih.gov/22782417/ - AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review — Cells · PubMed: https://pubmed.ncbi.nlm.nih.gov/34064363/ - What Athletes Should Know About AICAR and Other Prohibited AMP-Activated Protein Kinase Activators — U.S. Anti-Doping Agency (USADA): https://www.usada.org/spirit-of-sport/aicar-and-other-prohibited-amp-activated-protein-kinase-activators/ --- ## Glutathione Name: Glutathione Canonical URL: https://peptides.cx/library/glutathione Localized URLs: en: https://peptides.cx/library/glutathione; de: https://peptides.cx/de/library/glutathione; fr: https://peptides.cx/fr/library/glutathione; it: https://peptides.cx/it/library/glutathione; es: https://peptides.cx/es/library/glutathione; el: https://peptides.cx/el/library/glutathione; pl: https://peptides.cx/pl/library/glutathione; nl: https://peptides.cx/nl/library/glutathione; cs: https://peptides.cx/cs/library/glutathione; ro: https://peptides.cx/ro/library/glutathione; bg: https://peptides.cx/bg/library/glutathione; fi: https://peptides.cx/fi/library/glutathione; sv: https://peptides.cx/sv/library/glutathione; sk: https://peptides.cx/sk/library/glutathione; lt: https://peptides.cx/lt/library/glutathione Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: GSH, L-glutathione, reduced glutathione, gamma-L-glutamyl-L-cysteinyl-glycine Category: Skin / Cosmetic Evidence grade: C (C — Early / Preclinical) Regulatory status: Endogenous tripeptide sold as an oral dietary supplement in the US and much of the EU. No intravenous or injectable glutathione product is approved by the FDA or EMA. The US FDA has not approved glutathione for skin lightening and has warned that injectable skin-lightening products, including those containing glutathione, are unapproved and may be unsafe and ineffective. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: An antioxidant tripeptide made naturally by the body and widely sold as a supplement for skin lightening, 'detox', and anti-aging. Its endogenous biology is well established, but human evidence for the marketed benefits is weak to mixed. What is it: Glutathione (GSH) is a tripeptide of glutamate, cysteine, and glycine that the body synthesizes in nearly every cell, where it is the most abundant intracellular thiol antioxidant. It is central to redox balance and detoxification. The same molecule is separately marketed — as oral capsules, topicals, and intravenous infusions — for skin lightening and general 'wellness', which is a different question from its established internal biology. Proposed mechanisms: - Acts as the cell's principal thiol antioxidant, neutralizing peroxides and reactive electrophiles - Maintains cellular redox homeostasis and helps recycle other antioxidants such as vitamins C and E - Proposed skin-lightening mechanism is inhibition of tyrosinase and a shift toward lighter pheomelanin, largely inferred from in vitro and small clinical work - Synthesized intracellularly in two ATP-dependent steps, with glutamate-cysteine ligase as the rate-limiting enzyme Human evidence: Mixed and generally weak for the popular claims. Some randomized trials show that oral glutathione can raise body glutathione stores over months, while others found no change over shorter periods — results vary with dose, duration, and formulation. Evidence that oral or IV glutathione meaningfully lightens skin, 'detoxifies', or slows aging is limited, short-term, and often low-quality. Intravenous use for skin lightening is the least supported and most scrutinized: one reviewed dataset reported adverse events in about a third of participants, including liver dysfunction and a case of anaphylaxis. Animal / preclinical evidence: Animal and in vitro work established glutathione's core biology — antioxidant defense, detoxification, and redox signaling — and provides the mechanistic rationale for tyrosinase inhibition. This foundation is solid for the internal biology but does not demonstrate that supplementation produces the cosmetic outcomes marketed to consumers. Safety: Oral glutathione is generally well tolerated in trials, with mostly mild, transient gastrointestinal effects. The main safety concerns attach to injectable and intravenous use, especially for skin lightening: documented risks include liver and kidney effects, severe allergic reactions including anaphylaxis, and — because many products are compounded from non-sterile material — infection and contamination. Regulators including the US FDA have flagged injectable skin-lightening products as unapproved and potentially unsafe. Known side effects: - Mild gastrointestinal upset with oral use - Allergic reactions, including rare anaphylaxis, reported with intravenous use - Liver and kidney dysfunction reported in the context of IV skin-lightening use - Infection or contamination risk from non-sterile injections Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Glutathione: overview of its protective roles, measurement, and biosynthesis — Molecular Aspects of Medicine · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC2696075/ - Randomized controlled trial of oral glutathione supplementation on body stores of glutathione — European Journal of Nutrition · PubMed: https://pubmed.ncbi.nlm.nih.gov/24791752/ - Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review — Cureus · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC11862975/ --- ## NAD+ Name: NAD+ Canonical URL: https://peptides.cx/library/nad-plus Localized URLs: en: https://peptides.cx/library/nad-plus; de: https://peptides.cx/de/library/nad-plus; fr: https://peptides.cx/fr/library/nad-plus; it: https://peptides.cx/it/library/nad-plus; es: https://peptides.cx/es/library/nad-plus; el: https://peptides.cx/el/library/nad-plus; pl: https://peptides.cx/pl/library/nad-plus; nl: https://peptides.cx/nl/library/nad-plus; cs: https://peptides.cx/cs/library/nad-plus; ro: https://peptides.cx/ro/library/nad-plus; bg: https://peptides.cx/bg/library/nad-plus; fi: https://peptides.cx/fi/library/nad-plus; sv: https://peptides.cx/sv/library/nad-plus; sk: https://peptides.cx/sk/library/nad-plus; lt: https://peptides.cx/lt/library/nad-plus Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: NAD, nicotinamide adenine dinucleotide, NAD plus Category: Mitochondrial Evidence grade: C (C — Early / Preclinical) Regulatory status: NAD+ is a coenzyme, not a peptide and not an approved drug. No intravenous or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use; IV NAD+ is offered at clinics as an unapproved application. Among precursors, nicotinamide riboside (NR) is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the dietary-supplement definition. Risk flag: no Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A coenzyme — not a peptide — central to cellular energy metabolism, promoted via IV drips and precursor supplements (NR, NMN) for anti-aging and 'wellness'. Precursors reliably raise NAD+ levels, but human evidence for the anti-aging claims is limited. What is it: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, not a peptide. It shuttles electrons in redox reactions and serves as a substrate for enzymes such as sirtuins and PARPs involved in metabolism and DNA repair. Commercially it appears as direct intravenous or injectable NAD+, and as oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that the body converts into NAD+. Proposed mechanisms: - Serves as an essential electron carrier (NAD+/NADH) in glycolysis, the citric acid cycle, and oxidative phosphorylation - Acts as a required co-substrate for sirtuins, PARPs, and CD38, linking it to DNA repair and metabolic signaling - Oral precursors (NR, NMN) are metabolized through salvage pathways to raise intracellular NAD+ - Rationale for supplementation rests on reports that tissue NAD+ may decline with age, though this has been inconsistent in human data Human evidence: Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes — glucose and lipid metabolism, muscle strength, physical function — have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome. Animal / preclinical evidence: Preclinical studies in rodents and cell models are the main source of enthusiasm: raising NAD+ or its precursors has improved metabolic and some age-related measures in animals. However, human NAD+ dynamics differ from rodents, and these animal results have not translated cleanly into demonstrated clinical benefit in people. Safety: Oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects. Intravenous NAD+ is used at clinics but has little formal safety characterization; faster infusions are commonly associated with transient discomfort such as flushing, nausea, chest tightness, and cramping. Long-term safety of sustained NAD+ elevation in humans is not established. Known side effects: - Infusion-related flushing, nausea, chest tightness, and cramping with faster IV administration - Mild gastrointestinal upset, fatigue, or headache reported with oral precursors - Flushing with high-dose niacin forms - Unknown long-term effects of chronically elevated NAD+ in humans Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ — Frontiers in Aging Neuroscience · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/ - Clinical Evidence for Targeting NAD Therapeutically — Pharmaceuticals (Basel) · PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC7558103/ - NAD+ precursor supplementation in human ageing: clinical evidence and challenges — Nature Metabolism · PubMed: https://pubmed.ncbi.nlm.nih.gov/41083806/ --- ## Melatonin Name: Melatonin Canonical URL: https://peptides.cx/library/melatonin Localized URLs: en: https://peptides.cx/library/melatonin; de: https://peptides.cx/de/library/melatonin; fr: https://peptides.cx/fr/library/melatonin; it: https://peptides.cx/it/library/melatonin; es: https://peptides.cx/es/library/melatonin; el: https://peptides.cx/el/library/melatonin; pl: https://peptides.cx/pl/library/melatonin; nl: https://peptides.cx/nl/library/melatonin; cs: https://peptides.cx/cs/library/melatonin; ro: https://peptides.cx/ro/library/melatonin; bg: https://peptides.cx/bg/library/melatonin; fi: https://peptides.cx/fi/library/melatonin; sv: https://peptides.cx/sv/library/melatonin; sk: https://peptides.cx/sk/library/melatonin; lt: https://peptides.cx/lt/library/melatonin Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: N-acetyl-5-methoxytryptamine, Circadin (prolonged-release melatonin) Category: Sleep Evidence grade: B (B — Human, limited) Regulatory status: A hormone, not a peptide. Regulatory status varies by country: sold over-the-counter as a dietary supplement in the US (not FDA-approved for any medical condition), but prescription-only in the UK and several EU countries. The EMA has approved a prolonged-release melatonin product (Circadin) as a prescription treatment for primary insomnia in adults aged 55 and older. Risk flag: no Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A hormone, not a peptide, produced by the pineal gland to regulate the sleep-wake cycle. It is well studied for sleep-onset and circadian uses, where effects are consistent but modest; it is over-the-counter in the US but prescription-only in several European countries. What is it: Melatonin is a hormone — not a peptide — secreted mainly by the pineal gland in response to darkness, signaling that it is night and helping set the circadian clock. It acts on MT1 and MT2 receptors linked to the brain's master clock in the suprachiasmatic nucleus. It is regulated very differently around the world: an OTC supplement in the US, a prescription medicine in much of Europe. Proposed mechanisms: - Binds MT1 and MT2 receptors to promote sleep onset and shift circadian timing - Reinforces the day-night signal from the suprachiasmatic nucleus, acting as a 'chronobiotic' - Most useful when the internal clock is misaligned, as in jet lag, shift work, or delayed sleep-wake phase disorder - Has some antioxidant activity in preclinical models, though this is not the basis for its sleep use Human evidence: Comparatively well studied. Meta-analyses of randomized trials in primary sleep disorders find that melatonin modestly shortens the time to fall asleep (on the order of several minutes), modestly increases total sleep time, and improves subjective sleep quality; the absolute benefit is smaller than for standard prescription hypnotics. Evidence is stronger for circadian problems such as jet lag than for chronic insomnia — the American Academy of Sleep Medicine issued a weak recommendation against melatonin for chronic insomnia. A practical problem is product quality: an analysis of US melatonin gummies found actual content ranging from roughly three-quarters to more than three times the labeled amount. Animal / preclinical evidence: Animal studies underpin melatonin's role as a circadian signaling hormone and characterize its MT1/MT2 receptor pharmacology, phase-shifting effects, and antioxidant properties. These models explain how and when melatonin influences sleep timing but are not the primary basis for its human use claims. Safety: Melatonin has a favorable short-term safety profile, which is one reason it is often preferred over conventional hypnotics. Common effects are mild and include daytime drowsiness, headache, and dizziness. Because it is a hormone and because OTC labeling can be inaccurate, caution is reasonable for children, during pregnancy, and with long-term use. It can cause drowsiness and should not be combined with alcohol or used before driving. Known side effects: - Daytime sleepiness or grogginess - Headache - Dizziness - Vivid dreams, and occasional short-term mood changes Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Sources: - Melatonin (StatPearls) — StatPearls · NCBI Bookshelf: https://www.ncbi.nlm.nih.gov/books/NBK534823/ - Meta-analysis: melatonin for the treatment of primary sleep disorders — PLoS ONE · PubMed: https://pubmed.ncbi.nlm.nih.gov/23691095/ - Circadin (melatonin) — European public assessment report — European Medicines Agency: https://www.ema.europa.eu/en/medicines/human/EPAR/circadin --- ## GLOW (blend) Name: GLOW (blend) Canonical URL: https://peptides.cx/library/glow Localized URLs: en: https://peptides.cx/library/glow; de: https://peptides.cx/de/library/glow; fr: https://peptides.cx/fr/library/glow; it: https://peptides.cx/it/library/glow; es: https://peptides.cx/es/library/glow; el: https://peptides.cx/el/library/glow; pl: https://peptides.cx/pl/library/glow; nl: https://peptides.cx/nl/library/glow; cs: https://peptides.cx/cs/library/glow; ro: https://peptides.cx/ro/library/glow; bg: https://peptides.cx/bg/library/glow; fi: https://peptides.cx/fi/library/glow; sv: https://peptides.cx/sv/library/glow; sk: https://peptides.cx/sk/library/glow; lt: https://peptides.cx/lt/library/glow Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: GLOW blend, GHK-Cu / BPC-157 / TB-500 blend Category: Recovery / Regeneration Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine anywhere. GLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Its individual components (GHK-Cu, BPC-157, TB-500) are themselves unapproved as drugs, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A research-market blend combining GHK-Cu, BPC-157, and TB-500, marketed for recovery and skin. Blends like this have no evidence base of their own; at best they inherit the thin, mostly preclinical data on each separate component. What is it: GLOW is not a single compound but a fixed combination product, most commonly marketed as a blend of three research peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic peptide fragment), and TB-500 (a fragment related to thymosin beta-4). It is sold for soft-tissue recovery, skin, and 'wellness'. There is no standardized formula, and ratios differ between vendors. Proposed mechanisms: - No mechanism has been characterized for the blend as a whole; any rationale is extrapolated from the individual peptides - GHK-Cu is studied mainly in vitro and in topical cosmetics for effects on collagen and wound-healing signaling - BPC-157 is proposed, largely from rodent studies, to influence angiogenesis and tissue-repair pathways - TB-500 is proposed to affect cell migration and actin dynamics, again mainly from preclinical work - Combining three agents makes it impossible to attribute any observed effect or harm to a specific component Human evidence: None for the blend. No clinical trials have studied this GHK-Cu / BPC-157 / TB-500 combination in humans for safety or effectiveness. The individual components also lack robust human evidence: GHK-Cu's human data is largely limited to topical cosmetic use, and BPC-157 and TB-500 have essentially no adequately controlled human trials. Combining unproven agents does not create evidence — it removes the ability to tell which ingredient is responsible for any effect. Animal / preclinical evidence: Only indirect. Each component has some preclinical (mostly rodent or in vitro) literature, but there are no animal studies of this specific fixed-ratio blend, and preclinical results for the components have not been confirmed in humans. Safety: The safety of the blend is unknown. No formal human safety data exist for the combination, and fixed-ratio blends make it harder to identify the source of any adverse reaction or to adjust exposure to a single ingredient. Products are sold as research chemicals with variable composition and purity, adding contamination and mislabeling risk on top of the unknowns of each peptide. Known side effects: - Not characterized in humans; no reliable adverse-event data for the blend - Injection-site reactions reported anecdotally with the individual peptides - Unknown risks from combining multiple unapproved peptides - Contamination, mislabeling, and dose-uncertainty risks from research-chemical sourcing Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Source gap: No suitable primary study or review specific to this entry was identified during the last editorial review. --- ## KLOW (blend) Name: KLOW (blend) Canonical URL: https://peptides.cx/library/klow Localized URLs: en: https://peptides.cx/library/klow; de: https://peptides.cx/de/library/klow; fr: https://peptides.cx/fr/library/klow; it: https://peptides.cx/it/library/klow; es: https://peptides.cx/es/library/klow; el: https://peptides.cx/el/library/klow; pl: https://peptides.cx/pl/library/klow; nl: https://peptides.cx/nl/library/klow; cs: https://peptides.cx/cs/library/klow; ro: https://peptides.cx/ro/library/klow; bg: https://peptides.cx/bg/library/klow; fi: https://peptides.cx/fi/library/klow; sv: https://peptides.cx/sv/library/klow; sk: https://peptides.cx/sk/library/klow; lt: https://peptides.cx/lt/library/klow Transactional search intent: Vendor comparison with purchase data separated from editorial evidence. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Also known as: KLOW blend, KPV / GHK-Cu / BPC-157 / TB-500 blend Category: Recovery / Regeneration Evidence grade: D (D — Anecdotal) Regulatory status: Not an approved medicine anywhere. KLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Every component is itself an unapproved drug, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list. Risk flag: yes Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Summary: A research-market blend that stacks several peptides — commonly KPV, GHK-Cu, BPC-157, and TB-500, and in some versions LL-37 — marketed for recovery and inflammation. As with any blend, it has no evidence base of its own and only inherits the thin, mostly preclinical data on its components. What is it: KLOW is not a single compound but a multi-peptide blend sold on the research-chemical market. It is essentially the GLOW combination (GHK-Cu, BPC-157, TB-500) with the anti-inflammatory tripeptide KPV added, and some vendors also include the antimicrobial peptide LL-37. Exact composition and ratios are not standardized and vary between suppliers. Proposed mechanisms: - No mechanism is defined for the blend itself; rationale is borrowed from the separate peptides - KPV, a fragment of alpha-MSH, is studied mainly in vitro and in animal models for anti-inflammatory activity - LL-37, when included, is a human antimicrobial and host-defense peptide with context-dependent immune effects - GHK-Cu, BPC-157, and TB-500 contribute the same largely preclinical wound-healing rationale as in the GLOW blend - Stacking four or five agents makes attributing any benefit or harm to a single component effectively impossible Human evidence: None for the blend. No clinical trials have evaluated this KPV / GHK-Cu / BPC-157 / TB-500 (with or without LL-37) combination in humans. The components individually also lack robust human evidence for the marketed claims. Adding more unproven peptides increases uncertainty rather than confidence. Animal / preclinical evidence: Only indirect and component-level. KPV has anti-inflammatory activity in cell and rodent models; LL-37 is extensively studied in immunology; and GHK-Cu, BPC-157, and TB-500 each have preclinical repair-related literature. But no animal studies exist for this specific fixed blend. Safety: The safety of the blend is unknown. There is no human safety data for the combination, and including an immunologically active peptide such as LL-37 alongside several other unapproved agents raises the number of ways an adverse reaction could occur while removing any way to isolate the cause. Products are sold as research chemicals with variable composition and purity. Known side effects: - Not characterized in humans; no reliable adverse-event data for the blend - Injection-site reactions reported anecdotally with the individual peptides - LL-37 has context-dependent, potentially harmful immune effects that are poorly understood in this setting - Contamination, mislabeling, and dose-uncertainty risks from research-chemical sourcing Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence stated above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. Source gap: No suitable primary study or review specific to this entry was identified during the last editorial review. # Head-to-head comparisons (15) ### BPC-157 vs TB-500 / Thymosin Beta-4 URL: https://peptides.cx/compare/bpc-157-vs-tb-500 BPC-157 and TB-500 (a fragment associated with the protein Thymosin Beta-4) are two of the most frequently discussed peptides in the recovery and regeneration category. Both are often mentioned together in community conversations about soft-tissue and connective-tissue healing, and both are sold only as research chemicals rather than approved medicines. This page compares what each is actually researched for, side by side, as an educational reference. It is not medical advice and does not cover dosing, protocols, or sourcing. The honest headline is that neither peptide is backed by robust human clinical trials. BPC-157's reputation rests almost entirely on rodent studies and anecdotal reports, with peer-reviewed human trials essentially absent. TB-500's story is more nuanced: the natural protein Thymosin Beta-4 has been examined in some clinical contexts, but the specific research-market "TB-500" fragment lacks robust human data of its own. Read any comparison of these two with that evidence gap firmly in mind. Verdict: In research terms, BPC-157 is more associated with tendon, ligament, and gut-tissue healing, driven largely by a body of rodent studies, while TB-500 / Thymosin Beta-4 is more associated with cell migration, wound healing, and cardiac tissue repair, with the parent protein having appeared in some clinical contexts. Neither has robust human trials for the recovery uses discussed online, and both are unapproved research chemicals with unverified purity and safety. This comparison describes what each is more studied for, not a recommendation to use either; questions about health should go to a qualified professional. ### Semaglutide vs Tirzepatide URL: https://peptides.cx/compare/semaglutide-vs-tirzepatide Semaglutide and Tirzepatide are both metabolic peptides that have been characterised far more thoroughly in humans than the typical research peptide. Both are approved prescription medicines for type 2 diabetes and weight management, and both carry strong clinical trial evidence and extensive preclinical characterisation. This page is an educational reference that compares what each molecule is and what the published research base looks like — it is not medical advice, not a protocol, and not a source of these compounds. The core scientific distinction is receptor targeting. Semaglutide is a long-acting single-target GLP-1 receptor agonist, while Tirzepatide is a dual agonist that engages both the GIP and GLP-1 receptors. Both act on glucose-dependent insulin secretion, gastric emptying, and appetite regulation, but the dual-receptor design of Tirzepatide is the defining structural difference researchers point to. Below we lay the two side by side across mechanism, evidence, safety, and regulatory standing. Verdict: Both compounds are unusually well-researched for the peptide space — each has robust human clinical trial evidence and regulatory approval, which most research peptides lack. Semaglutide is the more studied single-target GLP-1 agonist with the longer approval history, while Tirzepatide is the reference molecule for dual GIP/GLP-1 receptor research. The meaningful difference is mechanistic — one target versus two — not a question of which is "better" for any individual. Both are prescription-only medicines that require medical supervision, and this comparison is educational only. ### Tirzepatide vs Retatrutide URL: https://peptides.cx/compare/tirzepatide-vs-retatrutide Tirzepatide and Retatrutide are both metabolic compounds that act on incretin and related hormone-receptor pathways, and they are frequently discussed together because both emerged from the same wave of research into multi-receptor agonists for glycemic control and weight regulation. The key structural difference is the number of receptors each engages: Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Retatrutide is a triple agonist that additionally targets the glucagon receptor. This page compares what each compound has been researched for, not which one anyone should use. The two sit at very different points on the evidence and regulatory spectrum. Tirzepatide has strong clinical trial evidence and is an approved prescription medicine for type 2 diabetes and weight management, meaning it must be used under medical supervision. Retatrutide remains investigational: Phase 2 trials have reported substantial weight loss and Phase 3 evaluation is ongoing, but it is not an approved medicine. Both carry meaningful safety considerations, and this comparison is an educational reference only, not medical advice, dosing guidance, or a recommendation to obtain or use either compound. Verdict: Tirzepatide is the far more researched and validated compound: it is an approved prescription medicine with strong clinical trial evidence for glycemic control and weight management. Retatrutide is more of a frontier research compound, adding glucagon-receptor activity to the dual-agonist template, with encouraging Phase 2 weight-loss data but no regulatory approval and an incomplete safety picture. In short, Tirzepatide is better established for approved diabetes and weight-management use, while Retatrutide is being investigated for obesity and metabolic disease. This is a comparison of what each is more researched for, not a recommendation to obtain or use either; both are restricted and Retatrutide remains investigational. ### Ipamorelin vs CJC-1295 URL: https://peptides.cx/compare/ipamorelin-vs-cjc-1295 Ipamorelin and CJC-1295 are both peptides in the growth-hormone secretagogue category, and they are frequently discussed together because they act on different arms of the same GH axis. Ipamorelin is a selective growth-hormone secretagogue that works through ghrelin-receptor pathways, while CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). This complementary mechanism is why the two names so often appear in the same conversation. It is important to be honest about the evidence: both peptides carry a "C" evidence grade on this site, meaning robust, modern human trial data is limited for each. Neither is an approved medicine for general use, and both sit in research-chemical territory with real hormonal risks. This page compares what each compound is and how it has been studied, not which one anyone should use. Nothing here is medical advice, a protocol, or a dosing recommendation. Verdict: These two peptides are studied for overlapping goals but through distinct mechanisms: Ipamorelin is more characterized as a selective ghrelin-receptor secretagogue, while CJC-1295 is more characterized as a GHRH-pathway analogue acting on a different part of the GH axis. Both share a "C" evidence grade, meaning neither has robust modern human trials, and both remain unapproved research chemicals with genuine hormonal risks. The honest takeaway is that they are researched for complementary roles within the same axis rather than one being better than the other. This is an educational comparison, not a recommendation to use either. ### GHRP-2 vs GHRP-6 URL: https://peptides.cx/compare/ghrp-2-vs-ghrp-6 GHRP-2 and GHRP-6 are closely related synthetic growth-hormone-releasing peptides (GHRPs). Both are classed as growth hormone secretagogues and both act primarily through the ghrelin receptor to stimulate the release of growth hormone from the pituitary. Because they share this core mechanism and belong to the same peptide family, they are frequently discussed side by side, and the differences between them are often subtle rather than categorical. Neither compound is an approved medicine for general use; both carry a research-chemical status and are flagged for hormonal risk. The published record for each is limited, consisting largely of pharmacological study history and preclinical work rather than robust, large-scale human trials. This page compares what each peptide has been more studied and discussed for, on an evidence basis only. It is an educational reference and not medical advice, and nothing here should be read as guidance to use either compound. Verdict: On the current record the two peptides are more alike than different: both are ghrelin-receptor growth hormone secretagogues with only limited human evidence and documented hormonal risks. The clearest distinction in the literature is emphasis, GHRP-6 is more consistently associated with strong appetite (ghrelin-like) effects, while GHRP-2 is discussed somewhat more as a GH-releasing agent. Neither is better validated than the other, and neither is an approved therapy. This is a comparison of what each has been more researched for, not a recommendation to use either. ### Semax vs Selank URL: https://peptides.cx/compare/semax-vs-selank Semax and Selank are two synthetic peptides that frequently appear side by side in nootropic discussions, largely because both were developed in Russia and are used clinically there while remaining unapproved in the EU and US. Semax is derived from a fragment of the ACTH hormone and is studied primarily for cognitive and neuroprotective effects, whereas Selank is an analogue of the endogenous immunomodulatory peptide tuftsin and is studied primarily for anxiolytic (anti-anxiety) effects. Both carry a comparable, limited evidence grade and share the same fundamental caveat: the bulk of published research originates from a narrow set of regional research groups, with limited independent replication elsewhere. This page compares the two on what each has been researched for, the mechanisms proposed in the literature, the strength of human versus animal evidence, and their regulatory standing. It is an educational reference, not medical advice. It does not cover dosing, protocols, or sourcing, and nothing here should be read as a recommendation to use either compound. The honest summary up front: neither peptide has the kind of large, independently replicated human trial base that would support strong efficacy claims, and research-market versions sold outside their regional approvals are of unverified purity. Verdict: Semax is the more researched of the two for cognitive and neuroprotective questions, while Selank is the more researched for anxiolytic and mood-related questions — reflecting their different parent molecules and research traditions. Neither has a robust, independently replicated human trial base, and both share a Grade C evidence level built largely on regional clinical use and preclinical work. This is a comparison of what each has been studied for, not a recommendation to use either; both remain unapproved in the EU and US, and research-market versions are of unverified purity. ### MOTS-c vs SS-31 (Elamipretide) URL: https://peptides.cx/compare/mots-c-vs-ss-31 MOTS-c and SS-31 (Elamipretide) are both often grouped under the "mitochondrial peptide" umbrella, but they are quite different molecules studied for different reasons. MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA, examined mostly in preclinical work for metabolism and exercise physiology, with proposed AMPK activation. SS-31 is a synthetic, cell-permeable peptide designed to target cardiolipin in the inner mitochondrial membrane, and it has been carried into controlled human clinical trials for mitochondrial disease. This page compares the two strictly as a research and evidence reference. Neither is an approved general-use medicine: MOTS-c sits at research-chemical status with mostly preclinical data, while SS-31 is investigational and has been studied in clinical trials with mixed results. Nothing here is medical advice, and no dosing, protocols, or sourcing are provided. The goal is to clarify what each peptide has actually been researched for and how strong that evidence currently is. Verdict: These peptides are researched for different questions, so "more researched for what" matters more than any ranking. SS-31 (Elamipretide) has the stronger and more clinically advanced evidence base, having reached controlled human trials for mitochondrial disease, though those trials have shown mixed results and it remains investigational. MOTS-c is studied more for metabolism and exercise physiology, but its evidence is largely preclinical and mechanistic, with limited human data. Neither is an approved medicine, and both carry unverified research-market supply concerns; this comparison describes their research profiles, not a recommendation to use either. ### Melanotan I vs Melanotan II URL: https://peptides.cx/compare/melanotan-1-vs-melanotan-2 Melanotan I and Melanotan II are both synthetic peptides in the melanocortin family, originally studied for their effects on skin pigmentation. Although their names sound like sequential versions of one product, they are distinct molecules with different receptor selectivity, different research trajectories, and different regulatory footprints. Melanotan I is structurally related to afamelanotide, a compound that has been developed into an approved medicine for a specific rare condition, whereas Melanotan II is a separate, non-selective melanocortin agonist that regulators have repeatedly flagged for safety concerns. This page is an educational reference that compares what each peptide has been researched for, not a recommendation to use either. It is important to be evidence-honest: for the research-market versions of these peptides, robust human clinical trial data is limited or absent, and much of what is characterized comes from preclinical work. Both carry documented risk flags, and neither research-market compound is an approved medicine. The comparison below focuses strictly on mechanism, evidence level, and regulatory status. Verdict: Melanotan I is the more researched of the two, largely because its close relative, afamelanotide, has been developed and approved as a medicine for a specific rare condition, giving that pathway a clinical evidence base. Melanotan II is a distinct, non-selective melanocortin agonist that lacks approval and has been the subject of repeated regulator safety warnings, and its site evidence score (C) reflects weaker support than Melanotan I's (B). Neither research-market compound is an approved medicine, and both carry documented risk flags, so this is a comparison of what each has been studied for, not a statement that either is safe or advisable to use. ### CJC-1295 vs Sermorelin URL: https://peptides.cx/compare/cjc-1295-vs-sermorelin CJC-1295 and Sermorelin are two peptides that come up constantly in the same conversation because they work on the same biological target: the growth-hormone-releasing hormone (GHRH) pathway. Sermorelin corresponds to the first 29 amino acids of GHRH (hence its alias GRF 1-29), while CJC-1295 is a synthetic analogue of GHRH built around that same active fragment. Both are categorized as growth hormone secretagogues, and both are intended to prompt the pituitary to release growth hormone rather than supplying growth hormone directly. This page is an educational, evidence-focused comparison, not medical advice and not a recommendation to use either compound. The honest picture is that neither has the kind of large, modern, controlled human trial base that would make either a validated therapy for general use. Sermorelin has more of a historical clinical footprint; CJC-1295 sits closer to pure research-chemical status. Below we compare what each is actually documented to do, how strong the evidence is, and where each stands with regulators. Verdict: Both peptides target the same GHRH-driven growth-hormone pathway and both carry only limited (grade C) human evidence, so neither is a validated therapy. The clearest difference is history: Sermorelin has an established prior clinical footprint, having been marketed as a medicine for diagnostic and therapeutic use, and is therefore the more studied of the two in a formal clinical sense. CJC-1295 remains closer to research-chemical status with only limited early clinical history. This is a comparison of what each is more researched for, not a suggestion to use either; anything affecting the GH axis carries real hormonal risks. ### IGF-1 LR3 vs MGF / PEG-MGF URL: https://peptides.cx/compare/igf-1-lr3-vs-mgf IGF-1 LR3 and MGF / PEG-MGF are both growth-factor compounds that sit within the insulin-like growth factor 1 (IGF-1) biology, which is why they are frequently compared. IGF-1 LR3 (Long R3 IGF-1) is a modified, long-acting IGF-1 analogue engineered for an extended half-life, while MGF (Mechano Growth Factor, also called IGF-1Ec) is a naturally occurring splice variant of the IGF-1 gene; PEG-MGF is a pegylated version discussed for a longer duration of action. Despite their shared lineage, they are distinct molecules studied in different research contexts. This page is an educational reference, not medical advice. It compares what each compound is more researched for, not which one anyone should use. A consistent theme across both is that robust human clinical evidence is lacking: much of what is discussed comes from mechanistic and animal work rather than controlled trials in people. Both are also unapproved research-market materials and are prohibited in sport, so any claims of benefit should be read with caution. Verdict: Both compounds are early-stage and lack robust human trials, so neither has a validated therapeutic profile. IGF-1 LR3 is more researched as a broadly acting, long-half-life IGF-1 receptor agonist, with animal data on growth and metabolic effects and a notable hypoglycaemia risk signal. MGF / PEG-MGF is discussed more specifically in the context of local muscle satellite-cell activation and repair signalling, though its human evidence is minimal and largely anecdotal. This comparison describes what each is more studied for, not a recommendation to use either. ### Tesamorelin vs Sermorelin URL: https://peptides.cx/compare/tesamorelin-vs-sermorelin Tesamorelin and Sermorelin are both peptides that act on the growth-hormone-releasing hormone (GHRH) pathway, prompting the pituitary to release the body's own growth hormone rather than supplying growth hormone directly. Because they share this GHRH-based mechanism, they are frequently grouped together and compared. They differ, however, in their molecular design and in how far each has been formally studied: Tesamorelin is a stabilised GHRH analogue, while Sermorelin corresponds to the first 29 amino acids of natural GHRH. This page is an educational reference that compares the two on the basis of published research and regulatory history, not a recommendation to use either. It offers no dosing, protocols, or sourcing guidance. A key theme is evidence honesty: Tesamorelin has clinical evidence supporting one specific approved indication, while broader and research-market uses of both peptides are not established therapies. Anything affecting the GH axis carries real hormonal effects and, per the source data, warrants medical supervision. Verdict: Tesamorelin is the more formally researched of the two, carrying a specific approved indication (HIV-associated lipodystrophy) backed by clinical evidence and a correspondingly higher editorial evidence score. Sermorelin has a longer history of earlier clinical and diagnostic use of the GHRH pathway, but its modern research-market use is not a validated therapy. Neither comparison endorses use: both act on the GH axis with real hormonal effects, both are restricted, and the appropriate framing is what each has been studied for, not which one to take. ### Epitalon vs Thymalin URL: https://peptides.cx/compare/epitalon-vs-thymalin Epitalon and Thymalin are both peptides that trace back to Russian gerontology and bioregulator research, and both are frequently discussed in longevity communities. Despite that shared origin, they sit in different categories and are studied for different purposes: Epitalon is a synthetic tetrapeptide talked about in relation to telomerase activity and the pineal gland, while Thymalin is a thymus-derived peptide preparation studied for immune modulation. This page compares what each has actually been researched for, not which one anyone should use. An honest look at the evidence matters here. Neither peptide is an approved medicine in the EU or US, and both are sold on the research-chemical market where material is unverified. Independent human data is limited for both, with much of the published work coming from a small number of originating research groups. Below we lay the two side by side across category, mechanism, human and animal evidence, safety, and regulatory status so you can see where the research is stronger and where it is thin. Verdict: These peptides are researched for different things, so this is not a case of one being better. Epitalon appears more often in longevity discussions tied to telomerase and circadian claims, but its evidence base is weak (rated D) and rests largely on a small number of originating research groups with limited independent replication. Thymalin is more associated with immune modulation and carries a somewhat stronger, though still limited, evidence rating (C), partly because it has seen regional clinical use as a medicine. For both, independent human data is thin and neither is an approved medicine in the EU or US. This comparison describes what each is more studied for, not a recommendation to use either. ### BPC-157 vs GHK-Cu URL: https://peptides.cx/compare/bpc-157-vs-ghk-cu BPC-157 and GHK-Cu are two very different peptides that often get grouped together in online discussion, but they sit in separate categories with very different levels of evidence. BPC-157 is a synthetic 15-amino-acid fragment derived from a protein found in gastric juice, discussed mainly around soft-tissue and gut recovery. GHK-Cu is a naturally occurring copper-binding tripeptide used widely as a topical cosmetic ingredient. This page compares what the research literature actually supports for each, not what either can do for any individual. The most important distinction is evidence quality and regulatory footing. GHK-Cu has a reasonable base of human topical cosmetic studies and is broadly permitted as a cosmetic ingredient. BPC-157, by contrast, has essentially no peer-reviewed human clinical trials; its reputation rests on rodent studies and anecdotal reports, and it is sold only as a research chemical with no authorisation for human use. Neither profile should be read as a recommendation to use either compound. This is an educational reference, not medical advice, and it contains no dosing, protocols, or sourcing guidance. Verdict: These two peptides are researched for different things and rest on very different evidence bases. GHK-Cu is the more established of the two for a specific, narrow use: topical skin appearance, where it has human cosmetic studies and broad regulatory acceptance as a cosmetic ingredient (evidence grade B). BPC-157 is more discussed for soft-tissue and gut recovery, but that reputation is built almost entirely on rodent studies and anecdote — it has essentially no human clinical trials and is sold only as an unapproved research chemical (evidence grade C). In short, GHK-Cu is better evidenced for topical skin use, while BPC-157 remains largely preclinical for recovery. This is a comparison of what each is more researched for, not a recommendation to use either. ### Kisspeptin-10 vs Gonadorelin URL: https://peptides.cx/compare/kisspeptin-10-vs-gonadorelin Kisspeptin-10 and Gonadorelin are both peptides that act on the reproductive hormone axis, which is why they are frequently mentioned together in endocrinology discussions. They sit at different points in the same signalling chain: Kisspeptin-10 (KP-10) acts upstream to stimulate the neurons that release GnRH, while Gonadorelin is synthetic GnRH itself, acting directly on the pituitary to trigger LH and FSH release. This page is an educational reference that compares what each peptide has been researched for. It is not medical advice, and it does not cover dosing, protocols, or sourcing. An important distinction is regulatory. Gonadorelin is an approved prescription medicine for specific endocrine indications in some jurisdictions and is used clinically in reproductive endocrinology. Kisspeptin-10 remains investigational and is used mainly in controlled clinical research settings, not as a general-use medicine. Both peptides carry real hormonal effects on the reproductive axis and are only appropriate under clinical or research supervision. Nothing here is a recommendation to use either compound. Verdict: Gonadorelin is the more established of the two: it is an approved prescription medicine for specific endocrine indications in some jurisdictions, with clinical evidence behind those approved uses. Kisspeptin-10 is more of a research tool — it has been studied in controlled clinical research on reproductive endocrinology but remains investigational rather than a general-use medicine. Their key difference is where they act: Kisspeptin-10 upstream on GnRH neurons, Gonadorelin as the GnRH signal on the pituitary. This is a comparison of what each is more researched for, not a recommendation to use either. ### Hexarelin vs GHRP-2 URL: https://peptides.cx/compare/hexarelin-vs-ghrp-2 Hexarelin and GHRP-2 are both synthetic growth-hormone secretagogues that act through the ghrelin receptor to prompt release of growth hormone. Because they belong to the same pharmacological family, they are frequently discussed side by side. This page is an educational reference that compares what each compound has actually been studied for, and where the evidence is thin. It is not medical advice and does not cover dosing, protocols, or sourcing. Both compounds sit in a research-chemical status: neither is an approved medicine for general use, and both carry a documented risk flag due to their hormonal activity. Their human evidence base is limited, resting largely on older pharmacological study history rather than robust clinical trials. Where claims exist about muscle, recovery, or performance effects, they are mostly mechanistic or preclinical rather than confirmed in controlled human research. The comparison below reflects the facts as catalogued in our reference database and does not endorse use of either compound. Verdict: Both Hexarelin and GHRP-2 are ghrelin-receptor growth-hormone secretagogues with only limited human evidence and shared hormonal risks, so neither has a robust clinical trial base. Hexarelin is the more distinctly studied for its potency and for discussed cardiovascular and desensitisation effects, while GHRP-2 is more associated in the literature with appetite stimulation alongside GH release. This is a summary of where research attention has fallen, not a recommendation to use either compound; both remain unapproved research chemicals. # Peptides by goal (9 hubs) ### Peptides Researched for Muscle Growth & Performance URL: https://peptides.cx/library/for/muscle-growth Researched peptides: Ipamorelin, CJC-1295, GHRP-6, GHRP-2, Hexarelin, IGF-1 LR3, MGF / PEG-MGF, Follistatin, Tesamorelin, Sermorelin Muscle growth and athletic performance are among the most searched contexts for peptide research, but the honest scientific picture is far more modest than online enthusiasm suggests. Most of the compounds discussed here fall into two families: growth-hormone secretagogues (peptides like ipamorelin, CJC-1295, the GHRPs, hexarelin, tesamorelin and sermorelin that prompt the body to release its own growth hormone) and direct growth-factor or myostatin-pathway agents (IGF-1 LR3, MGF and follistatin). They are grouped together because they touch the same biological levers — the GH/IGF-1 axis and muscle-signalling pathways — not because any of them is a proven muscle-building therapy. The evidence base is thin. Across this list, most peptides carry a "C" (early/preclinical) or "D" (anecdotal) evidence rating: their effects on growth-hormone release or muscle signalling are documented mostly in animal models and mechanistic studies, with little or no controlled human trial data for muscle growth specifically. Follistatin and MGF in particular have essentially no validated human evidence for research-market use, and IGF-1 LR3 is a potent growth factor with real risks and scant human safety data. Almost every peptide here is prohibited in competitive sport and sold only under "research chemical" status. This page is an educational reference, not medical advice, and it does not recommend, rank, or tell anyone what to take. There is no dosing, protocol, stacking, or sourcing information here — the goal is simply to show which peptides are studied in the muscle-growth context and what the science honestly does and does not establish. Tesamorelin and sermorelin have prescription histories for specific medical conditions and are discussed for education only; they are never promoted or sourced here. Manipulating the growth-hormone or IGF-1 axis carries genuine hormonal risks, and none of these compounds should be treated as a safe or established route to muscle gain. ### Peptides Researched for Recovery & Healing URL: https://peptides.cx/library/for/recovery-healing Researched peptides: BPC-157, TB-500 / Thymosin Beta-4, GHK-Cu, KPV, MGF / PEG-MGF Recovery and healing is one of the most active topics in the peptide research community, and it is also one where the gap between enthusiasm and evidence is widest. The peptides most often discussed here — BPC-157, TB-500, GHK-Cu, KPV, and MGF — are studied for their proposed roles in soft-tissue repair, angiogenesis, cell migration, and inflammation. This page is an educational reference to which peptides are researched in the recovery context and what the science honestly shows, not a recommendation to use any of them. The honest landscape is this: most of these compounds rest on animal, in-vitro, or mechanistic data rather than controlled human trials. BPC-157 and TB-500 have generated a large body of rodent healing studies but essentially no peer-reviewed human clinical evidence. KPV and MGF are even earlier-stage, largely preclinical and anecdotal. GHK-Cu is the exception with reasonable human evidence — but that evidence is for topical cosmetic use, not injected or systemic recovery. Where community claims about human healing exist, they are typically extrapolated from animals or from personal reports, not from trials. Most of these are sold only as research chemicals and are not approved medicines for human use; several are prohibited in sport. Research-grade material is not quality-assured for purity, sterility, or dosing, and long-term safety profiles are largely unknown. Nothing here is medical advice, a protocol, or a suggestion of what to take — it is a summary of what is being researched and how strong (or weak) that evidence currently is. Decisions about injury, healing, and health belong with a qualified clinician. ### Peptides Researched for Longevity & Anti-Aging URL: https://peptides.cx/library/for/longevity-antiaging Researched peptides: Epitalon, MOTS-c, SS-31 (Elamipretide), Humanin, FOXO4-DRI, Thymalin, Pinealon Longevity is one of the most speculative corners of peptide research. The compounds gathered on this page are studied — in cells, in animals, and occasionally in small human cohorts — for their proposed roles in aging biology: telomere maintenance, mitochondrial function, clearance of senescent cells, and so-called "bioregulation" of gene expression. This is a reference for understanding which peptides appear in that conversation and what the science actually supports, not a recommendation to use any of them. The honest picture is that robust human longevity evidence is essentially nonexistent here. Several of these peptides (epitalon, pinealon, thymalin) come from a single Russian gerontology and bioregulator research tradition whose findings have seen limited independent replication. Others (MOTS-c, humanin) are genuine mitochondrial-derived peptides with interesting biology but mostly preclinical and mechanistic data. FOXO4-DRI is an experimental senolytic with no human data and a risk flag. Only SS-31 (elamipretide) has been through controlled clinical trials — and those were for mitochondrial disease, with mixed results, and it is not an approved general-use medicine. None of these are approved anti-aging treatments. Most carry research-chemical status, and research-market material is unverified and not the same as any studied clinical product. Where a peptide is an investigational or regionally-approved medicine, it is discussed here strictly for education — never promoted, never sourced, and never a substitute for a licensed clinician's judgment. Treat every longevity claim in this space with caution: the gap between an intriguing mechanism and a proven human benefit is wide, and for these peptides it has not been closed. ### Peptides Researched for Fat Loss & Metabolic Health URL: https://peptides.cx/library/for/fat-loss-metabolic Researched peptides: AOD-9604, MOTS-c, Tesamorelin, Semaglutide, Tirzepatide, Retatrutide, Liraglutide Fat loss and metabolic health is one of the most talked-about areas in peptide research, but the honest picture is far more mixed than the marketing suggests. The compounds gathered here span a wide evidence spectrum: at one end sit approved prescription medicines with large randomized clinical trials behind them, and at the other sit research-market peptides whose human data is thin, observational, or entirely absent. This page is an educational reference to which peptides are studied in a metabolic context and what the evidence actually shows — not a recommendation, protocol, or guide to which to use. Most of the non-prescription peptides in this space lack robust human trials. AOD-9604, a growth-hormone fragment once developed for obesity, did not demonstrate sufficient efficacy in clinical trials to win approval. MOTS-c, a mitochondrial-derived peptide, is supported mostly by rodent and mechanistic work, with limited human data. Where you see dramatic before-and-after claims for these compounds online, the underlying clinical evidence generally does not match the promise, and long-term safety profiles remain unknown. The compounds with the strongest data are, unsurprisingly, the approved and investigational medicines. Semaglutide, tirzepatide, and liraglutide are approved prescription drugs for diabetes and weight management; retatrutide is an investigational triple agonist still in clinical trials; and tesamorelin is approved for a specific condition. These are included strictly for educational context — they are real medicines with real effects that belong under medical supervision. peptides.cx is not the seller and does not source these compounds; where a shop link appears it is labelled advertising. Nothing here is medical advice or a suggestion that anyone use them. ### Peptides Researched for Skin, Hair & Beauty URL: https://peptides.cx/library/for/skin-hair-beauty Researched peptides: GHK-Cu, Argireline, Matrixyl, SNAP-8, Melanotan I, Melanotan II Skin and hair is one of the most crowded corners of the peptide world, and also one of the most misunderstood. Several of the compounds discussed here — GHK-Cu, Argireline, Matrixyl and SNAP-8 — are topical cosmetic ingredients, not injectables, and they sit on a genuinely different footing from most research peptides: cosmetic use is broadly permitted, and there are published cosmetic studies reporting modest improvements in the appearance of skin. That does not make them miracle actives. The better-studied topicals carry a "B" grade of evidence at best, the effects reported are on appearance rather than deep structural change, and much of the mechanistic story ("stimulates collagen", "relaxes expression lines at the skin surface") remains discussed rather than definitively proven in humans. Beyond the cosmetic shelf, the picture gets more cautious quickly. GHK-Cu has reasonable topical data but is far less studied when injected or used systemically — a distinction that matters a great deal. The pigmentation peptides, Melanotan I and Melanotan II, are a different category altogether: these are melanocortin agonists flagged by regulators, not cosmetic ingredients. A compound related to Melanotan I (afamelanotide) is an approved medicine for a rare condition, but research-market versions are unregulated, and Melanotan II in particular has drawn multiple regulator safety warnings over effects on moles, blood pressure and other systems. This page is an educational reference, not medical or cosmetic advice. It maps which peptides are most researched in a skin, hair and beauty context and what the evidence honestly supports — not what anyone should take, how to use it, or where to obtain it. Most of these compounds lack robust, large-scale human trials for the benefits people associate with them, and we say so plainly. Prescription or regulator-flagged items are described for education only; nothing here is a recommendation, an endorsement, or a health claim. ### Peptides Researched for Sleep & Stress URL: https://peptides.cx/library/for/sleep-stress Researched peptides: DSIP, Selank Sleep and stress are among the most common reasons people search for peptide research, and a small number of compounds recur in that conversation. This page is an educational reference to which peptides are most often studied in the sleep and stress context, and what the published evidence honestly shows. It is not medical advice, and nothing here is a protocol, a dosing guide, or a recommendation to use any substance. The honest picture is that the evidence base here is thin. DSIP (delta sleep-inducing peptide) was named decades ago for its apparent link to sleep, but the human studies are old and produced mixed, inconsistent results. Selank, a synthetic analogue of the endogenous peptide tuftsin, has been studied for anxiolytic effects and is used as a medicine in a few countries, but independent replication outside those regional approvals is limited. Neither is an approved medicine in the EU or US, and both carry research-chemical status with unverified purity on the research market. Because robust, large-scale human trials are largely absent, claims about these peptides for sleep or stress should be read with caution. The goal of this page is to describe the research landscape accurately, not to promote any compound. Where a peptide is approved as a medicine in some jurisdiction, that context is noted for education only and is never an endorsement or a sourcing suggestion. ### Peptides Researched for Cognition & Focus URL: https://peptides.cx/library/for/cognitive-focus Researched peptides: Semax, N-Acetyl Semax Amidate, Selank, Cerebrolysin, Dihexa, Pinealon Cognition and focus are among the most discussed reasons people look into peptides, yet this is also one of the areas where the gap between online enthusiasm and solid science is widest. The peptides gathered on this page — Semax, N-Acetyl Semax Amidate, Selank, Cerebrolysin, Dihexa and Pinealon — appear frequently in nootropic conversations, but they sit at very different points on the evidence spectrum. This page is an educational reference on which peptides are studied in the cognition and focus context and what the research honestly shows. It is not medical advice, and nothing here is a protocol, dose, or recommendation to use anything. A recurring theme is that robust, independently replicated human trials are largely absent. Several of these compounds — Semax, Selank and Cerebrolysin — are approved or used as prescription medicines in some countries (notably Russia and parts of Eastern Europe) but are not approved in the EU or US, and much of their clinical evidence comes from a limited number of regional research groups rather than broad independent replication. Others, such as Dihexa and Pinealon, are research-status compounds with essentially no human data at all. Mechanisms often cited — modulation of BDNF, neurotrophic and neuroprotective signalling, or effects on synapse formation — are drawn mostly from preclinical and animal work. Because these compounds are studied and discussed for education only, this page does not rank them or recommend them for personal use; where a shop link appears it is labelled advertising, not a recommendation. Where an item is an approved medicine in some jurisdictions, that status is noted so it can be understood in context — it does not imply the research-market material sold online is the same, verified, or safe. Treat every claim below as a description of the research landscape, not a health claim or guarantee, and consult a qualified clinician for anything concerning your own health. ### Peptides Researched for Gut & Immune Health URL: https://peptides.cx/library/for/gut-immune Researched peptides: KPV, BPC-157, LL-37, Thymosin Alpha-1, VIP Gut and immune health is one of the most frequently discussed contexts in the research-peptide community, largely because several small peptides show intriguing anti-inflammatory or immune-modulating activity in laboratory and animal models. This page is an educational reference to the peptides most often researched in this space — it is not medical advice, and nothing here is a protocol, dosing guide, or recommendation to use any compound. It is important to be honest about the evidence. For most of the peptides listed here, robust human clinical trials are absent or very limited, and much of what is claimed is extrapolated from preclinical (cell and rodent) studies rather than demonstrated in controlled human research. Several are sold only as research chemicals and are not approved medicines, meaning purity, sterility, and safety of research-grade material are unverified. Where a peptide is an approved medicine in some countries, we note that — it is discussed here strictly for educational context, never promoted or sourced. Use this page to understand which peptides are being researched in the gut and immune context and what the science currently does and does not support. It is not a substitute for professional medical care, and questions about your own health should go to a qualified clinician. ### Peptides Researched for Sexual & Hormonal Health URL: https://peptides.cx/library/for/sexual-hormonal Researched peptides: PT-141 (Bremelanotide), Kisspeptin-10, Gonadorelin Sexual and hormonal health is one of the most searched-for topics in peptide science, but it is also one where the gap between laboratory interest and validated human therapy is widest. The peptides discussed in this context act on very different parts of the body: some target the brain's melanocortin system, while others sit at the top of the reproductive hormone axis that governs LH, FSH and downstream sex hormones. Grouping them together reflects shared research themes, not interchangeable uses or shared evidence. This page is an educational reference, not medical advice. It describes which peptides are researched in the sexual and hormonal health context and what the evidence honestly shows — it does not recommend, rank, or tell you what to use, and it contains no dosing, protocols, or sourcing. Several of these compounds directly affect the reproductive hormone axis or blood pressure, which is exactly why the ones with real clinical footing are prescription-only medicines that require professional supervision. Manipulating hormonal systems without oversight carries genuine risks. An honest reading of the landscape is mixed. PT-141 (Bremelanotide) has clinical evidence supporting a specific approved indication and exists as a licensed prescription medicine. Gonadorelin is likewise an approved medicine for defined endocrine uses. Kisspeptin-10 remains investigational, studied in controlled research settings rather than sold as a consumer product. Across all three, material sold on the unregulated research market is not the same as the studied clinical product, and its purity and identity are unverified. Where an item is an approved medicine, it is noted here strictly for education — never promoted, ranked, or sourced. # Knowledge base — foundational articles ### What Are Peptides? A Complete Beginner's Guide URL: https://peptides.cx/learn/what-are-peptides Peptides are short chains of amino acids linked by peptide bonds. They act as the body's signaling molecules, sitting between single amino acids and full-sized proteins, and are studied widely as medicines. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8844085/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10968328/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10614431/, https://imb.uq.edu.au/article/2017/11/explainer-peptides-vs-proteins-whats-difference, https://chem.libretexts.org/Courses/American_River_College/CHEM_309:_Applied_Chemistry_for_the_Health_Sciences/09:_Proteins_-_An_Introduction/9.03:_The_Peptide_Bond ### Peptides vs Proteins: What's the Difference? URL: https://peptides.cx/learn/peptides-vs-proteins Peptides and proteins are built from the same amino acids and the same chemical bond; the main thing separating them is size, and the dividing line is a useful convention rather than a hard law of nature. Sources: https://imb.uq.edu.au/article/2017/11/explainer-peptides-vs-proteins-whats-difference, https://www.bachem.com/knowledge-center/peptides-amino-acids-for-beginners-understanding-the-basics/, https://www.ncbi.nlm.nih.gov/books/NBK555990/, https://en.wikipedia.org/wiki/Peptide ### Peptides vs Hormones: How They Relate URL: https://peptides.cx/learn/peptides-vs-hormones "Peptide" and "hormone" are not opposites — they answer different questions. A peptide is a chemical structure; a hormone is a biological job. Many of the body's most important hormones, including insulin, GLP-1, and growth hormone, are peptides. Sources: https://www.ncbi.nlm.nih.gov/books/NBK541112/, https://www.ncbi.nlm.nih.gov/books/NBK538498/, https://pmc.ncbi.nlm.nih.gov/articles/PMC4020673/, https://med.libretexts.org/Courses/Southern_Illinois_University_Edwardsville/Essentials_of_Physiology_for_Nurse_Anesthetists_I_(Gopalan)/07:_Endocrine_Physiology/7.05:_Types_of_Hormones ### How Do Peptides Work? Mechanisms Explained URL: https://peptides.cx/learn/how-peptides-work Peptides act mainly as molecular keys: they bind cell-surface receptors with high precision and set off internal signaling cascades. This guide explains receptor binding, GPCRs, second messengers, agonists versus antagonists, why peptides are so specific, and why most are injected. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC4633518/, https://pmc.ncbi.nlm.nih.gov/articles/PMC3690506/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10330351/, https://pmc.ncbi.nlm.nih.gov/articles/PMC9866634/, https://pmc.ncbi.nlm.nih.gov/articles/PMC2792531/ ### How Peptides Are Made: Synthesis & Quality URL: https://peptides.cx/learn/how-peptides-are-made Most peptides are built one amino acid at a time on a solid resin, then purified by HPLC and freeze-dried. Understanding those steps explains why purity varies between batches and vendors, and why a certificate of analysis is the only real evidence of quality. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC4077397/, https://pmc.ncbi.nlm.nih.gov/articles/PMC4975908/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12447389/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12890753/ ### Peptide Half-Life, Stability & Delivery Explained URL: https://peptides.cx/learn/peptide-half-life-and-delivery Most peptides are broken down within minutes by enzymes and cleared quickly by the kidneys, which is why so few can be taken as pills. This guide explains the science of peptide half-life, the barriers to oral delivery, and the modifications chemists use to make peptides last longer. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8844085/, https://pmc.ncbi.nlm.nih.gov/articles/PMC8301568/, https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2026.1776167/full, https://pmc.ncbi.nlm.nih.gov/articles/PMC8903268/ ### Understanding Peptide Evidence: From Anecdote to Clinical Trial URL: https://peptides.cx/learn/understanding-peptide-evidence Not all peptide "research" carries equal weight. This guide explains the evidence hierarchy, why most animal results never reach humans, and how to judge a study before trusting its conclusion. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6409418/, https://pmc.ncbi.nlm.nih.gov/articles/PMC6631915/, https://journals.sagepub.com/doi/10.1177/02611929231157756, https://en.wikipedia.org/wiki/Hierarchy_of_evidence, https://pmc.ncbi.nlm.nih.gov/articles/PMC12064251/, https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products ### Peptide Safety, Side Effects & Contamination Risks URL: https://peptides.cx/learn/peptide-safety-and-risks Peptides are often described as low-risk, but the honest picture is more nuanced. This overview explains known side effects, the serious problem of contamination in unregulated products, immunogenicity, and why "research use only" status leaves major safety questions unanswered. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12010466/, https://pubmed.ncbi.nlm.nih.gov/37467878/, https://theconversation.com/the-peptide-problem-hype-is-outrunning-the-evidence-280715, https://acslabtest.com/blog/endotoxin-heavy-metal-testing-peptides, https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/ ### What 'Research Peptides' Really Means URL: https://peptides.cx/learn/research-peptides-explained The "research peptides" label is a regulatory and commercial classification, not a description of quality or safety. This guide explains what the label means, why peptides are sold this way, and what third-party testing does and does not verify. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8844085/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10330351/, https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/, https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/ ### How to Read a Peptide Certificate of Analysis (COA) URL: https://peptides.cx/learn/how-to-read-a-coa A Certificate of Analysis is a batch-specific lab report. This guide explains how to read each section — HPLC purity, mass spec identity, and safety tests — and how to spot fakes. Sources: https://pubmed.ncbi.nlm.nih.gov/18604941/, https://pmc.ncbi.nlm.nih.gov/articles/PMC6384780/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11341359/, https://www.usp.org/harmonization-standards/pdg/general-methods/bacterial-endotoxins ### Peptide Legality & Regulation: EU, US & Beyond URL: https://peptides.cx/learn/peptide-regulation-eu-us Peptides span three very different legal worlds: FDA- and EMA-approved medicines, pharmacy-compounded preparations, and unapproved "research" chemicals. This explainer maps how each is regulated across the US, EU, anti-doping sport, and other countries. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11945313/, https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/, https://natlawreview.com/article/tiny-chains-big-changes-what-fdas-latest-actions-mean-peptide-compounding, https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management, https://www.bscg.org/wada-prohibited-list-banned-drugs-and-supplement-risks ### Peptide Glossary: Key Terms Explained URL: https://peptides.cx/learn/peptide-glossary A plain-language reference glossary defining the biochemistry, pharmacology, pharmacokinetics, and manufacturing terms you encounter when reading about peptides. Educational only, grounded in the scientific literature. Sources: https://pubmed.ncbi.nlm.nih.gov/32494050/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12322139/, https://www.ncbi.nlm.nih.gov/books/NBK554498/, https://pmc.ncbi.nlm.nih.gov/articles/PMC3975427/ # Research digest — evidence roundups ### The State of GLP-1 & Incretin Research in 2026 URL: https://peptides.cx/research/state-of-glp-1-research-2026 A 2026 evidence roundup of GLP-1, GIP and dual/triple incretin agonists: approved uses, the trial landscape, what is next, and the honest gap between prescription medicine and the unapproved research-peptide market. Sources: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1431292/full, https://pmc.ncbi.nlm.nih.gov/articles/PMC12785922/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12277595/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12498447/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/ ### BPC-157: What the Evidence Actually Shows URL: https://peptides.cx/research/bpc-157-what-the-evidence-shows BPC-157 has a large and consistent animal literature but almost no published human trial data. This review separates what is genuinely known from what remains unproven, and explains why the online enthusiasm outruns the evidence. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/, https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products, https://clinicaltrials.gov/study/NCT07437547, https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act ### Peptide Regulation in 2026: What Changed URL: https://peptides.cx/research/peptide-regulation-2026 2026 reshaped the peptide landscape: the FDA moved to close the GLP-1 compounding window, left popular "research" peptides like BPC-157 and TB-500 in legal limbo pending advisory review, while the EMA fought falsified pens and WADA tightened its doping bans. Here is what actually changed. Sources: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list, https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/, https://www.healthlawadvisor.com/fda-proposal-would-leave-semaglutide-tirzepatide-and-liraglutide-off-503b-bulks-list, https://www.ema.europa.eu/en/news/ema-alerts-eu-patients-healthcare-professionals-reports-falsified-ozempic-pens, https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists, https://about.fiba.basketball/en/news/wada-list-of-prohibited-substances-and-methods-in-effect-for-2026 ### Longevity Peptides: An Evidence Map URL: https://peptides.cx/research/longevity-peptides-evidence-map A structured, citation-grounded review of the peptides most associated with longevity — what each one is, where the evidence is genuinely strong, where it is only preclinical, and where marketing has raced ahead of the science. Sources: https://www.jci.org/articles/view/158449, https://pmc.ncbi.nlm.nih.gov/articles/PMC7343442/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12411320/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/, https://pubmed.ncbi.nlm.nih.gov/14523363/ ### Growth Hormone Peptides: A Secretagogue Evidence Roundup URL: https://peptides.cx/research/growth-hormone-peptides-roundup Growth hormone secretagogues coax the pituitary into releasing its own GH. This roundup separates the two mechanistic families, flags which molecules have genuine clinical histories, and is honest about the thin evidence behind performance and anti-aging claims. Sources: https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9, https://en.wikipedia.org/wiki/Macimorelin, https://en.wikipedia.org/wiki/Sermorelin, https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams, https://www.drugs.com/wada/s2-peptide-hormones-growth-factors-and-related-substances.html, https://www.hcplive.com/view/fda-approves-aeterna-zentaris-macimorelin-growth-hormone-deficiency-test ### Do Cosmetic Peptides Actually Work? The Science URL: https://peptides.cx/research/do-cosmetic-peptides-work Topical cosmetic peptides show real but modest effects in controlled trials, and the central scientific challenge — getting an intact peptide through the skin barrier — separates genuine data from marketing. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12193160/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10005804/, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1618306/full, https://pubmed.ncbi.nlm.nih.gov/18492182/, https://pubmed.ncbi.nlm.nih.gov/27451932/ ### Research Peptide Quality & Contamination in 2026 URL: https://peptides.cx/research/research-peptide-quality-2026 The research-peptide market is largely unregulated, and independent testing repeatedly finds purity, dosing and contamination far outside label claims. This guide explains what quality means analytically and how buyers can assess it. Sources: https://pubmed.ncbi.nlm.nih.gov/25044089/, https://pubmed.ncbi.nlm.nih.gov/24771717/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11297364/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11582493/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11341359/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12722964/ ### Nootropic Peptides: Semax, Selank & the Evidence URL: https://peptides.cx/research/nootropic-peptides-evidence Semax, Selank, cerebrolysin and dihexa are the peptides most often marketed as "nootropics." The mechanistic science is genuinely interesting, but the human evidence is thin, mostly regional, and rarely replicated to Western standards. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6478305/, https://www.cochrane.org/evidence/CD008900_cerebrolysin-vascular-dementia, https://pmc.ncbi.nlm.nih.gov/articles/PMC11498467/, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00031/full, https://www.globenewswire.com/news-release/2024/09/03/2940069/0/en/Athira-Pharma-Announces-Topline-Results-from-Phase-2-3-LIFT-AD-Clinical-Trial-of-Fosgonimeton-for-Mild-to-Moderate-Alzheimer-s-Disease.html, https://en.wikipedia.org/wiki/Dihexa # Community forum index (104 threads / 362 posts) Each thread below is an indexable discussion page with DiscussionForumPosting schema. ### Muscle Growth & Performance URL: https://peptides.cx/forum/muscle-growth - [Welcome to Muscle Growth & Performance — read this before posting](https://peptides.cx/forum/muscle-growth/welcome-muscle-growth-read-first) — 2 replies - [GH secretagogues and safety — what should someone actually read up on?](https://peptides.cx/forum/muscle-growth/gh-secretagogue-safety-what-should-i-be-reading) — 3 replies - [IGF-1 LR3 and MGF — what does the 'LR3' actually mean and why the confusion with MGF?](https://peptides.cx/forum/muscle-growth/igf1-lr3-and-mgf-what-does-lr3-even-mean) — 3 replies - [Follistatin and myostatin inhibition — is any of the muscle hype supported yet?](https://peptides.cx/forum/muscle-growth/myostatin-follistatin-hype-check) — 2 replies - [Can someone explain the CJC-1295 vs Ipamorelin mechanism difference in plain English?](https://peptides.cx/forum/muscle-growth/cjc1295-vs-ipamorelin-mechanism-difference) — 3 replies - [Which peptides are actually researched for muscle vs just hyped?](https://peptides.cx/forum/muscle-growth/which-peptides-actually-researched-for-muscle) — 3 replies ### Recovery & Healing URL: https://peptides.cx/forum/recovery-healing - [Read first: Recovery & Healing — what this space is (and isn't)](https://peptides.cx/forum/recovery-healing/welcome-recovery-healing-rules-resources) — 2 replies - [Honest discussion: how much does the thin human evidence bother you?](https://peptides.cx/forum/recovery-healing/how-much-does-limited-human-evidence-bother-people) — 3 replies - [Newcomer question: TB-500 vs BPC-157 — what is each one actually researched for?](https://peptides.cx/forum/recovery-healing/tb500-vs-bpc157-what-are-they-even-researched-for) — 3 replies - [GHK-Cu: what's the research actually about — skin, or deeper connective tissue?](https://peptides.cx/forum/recovery-healing/ghk-cu-topical-vs-injectable-skin-connective-tissue) — 2 replies - [My 6-week experience journaling an Achilles tendinopathy flare (personal anecdote)](https://peptides.cx/forum/recovery-healing/bpc157-achilles-tendinopathy-6-week-anecdote) — 3 replies ### Longevity & Anti-Aging URL: https://peptides.cx/forum/longevity-antiaging - [Start here: what this category is (and isn't) for](https://peptides.cx/forum/longevity-antiaging/welcome-longevity-antiaging-scope-and-rules) — 2 replies - [Is Humanin the most underrated of the mitochondrial-derived peptides?](https://peptides.cx/forum/longevity-antiaging/humanin-underrated-mitochondrial-peptide) — 2 replies - [FOXO4-DRI: is the senolytic promise holding up 8 years on?](https://peptides.cx/forum/longevity-antiaging/foxo4-dri-senolytic-hype-check) — 2 replies - [MOTS-c as an 'exercise mimetic' — how strong is that framing really?](https://peptides.cx/forum/longevity-antiaging/mots-c-exercise-mimetic-how-strong) — 2 replies - [How does SS-31 (elamipretide) actually work at the mitochondrial membrane?](https://peptides.cx/forum/longevity-antiaging/ss31-elamipretide-cardiolipin-mechanism) — 2 replies - [Epitalon and telomerase: what does the actual evidence show?](https://peptides.cx/forum/longevity-antiaging/epitalon-telomerase-claims-vs-actual-evidence) — 3 replies ### Fat Loss & Metabolic URL: https://peptides.cx/forum/fat-loss-metabolic - [Start here: how we talk about fat-loss peptides and GLP-1s (rules + reading list)](https://peptides.cx/forum/fat-loss-metabolic/welcome-fat-loss-metabolic-rules) — 2 replies - [My honest experience thinking about peptides for fat loss (why I mostly didn't) — anecdote, not advice](https://peptides.cx/forum/fat-loss-metabolic/sharing-my-experience-losing-recomping-caveats-anecdote) — 3 replies - [Understanding how the GLP-1 class works (education only) — appetite, gastric emptying, the incretin story](https://peptides.cx/forum/fat-loss-metabolic/how-do-glp-1-drugs-actually-work-education-thread) — 3 replies - [MOTS-c: is the 'exercise mimetic' framing supported, or is it mostly mouse data?](https://peptides.cx/forum/fat-loss-metabolic/mots-c-mitochondrial-peptide-hype-vs-what-we-know) — 3 replies - [Tesamorelin and visceral fat — what population was it actually studied in?](https://peptides.cx/forum/fat-loss-metabolic/tesamorelin-visceral-fat-what-population-was-it-studied-in) — 2 replies - [AOD-9604: what does the actual human evidence say vs the marketing?](https://peptides.cx/forum/fat-loss-metabolic/aod-9604-what-does-the-actual-evidence-say) — 3 replies ### Skin, Hair & Beauty URL: https://peptides.cx/forum/skin-hair-beauty - [Welcome to Skin, Hair & Beauty — start here (rules + what this category is for)](https://peptides.cx/forum/skin-hair-beauty/welcome-skin-hair-beauty-read-first) — 2 replies - [Pigmentation peptides (Melanostatine-5 etc.) — worth it vs the usual brightening actives?](https://peptides.cx/forum/skin-hair-beauty/pigmentation-peptides-melanostatine-hydroxyproline-vs-established-actives) — 2 replies - [Hair peptides — copper peptides, biotinyl-GHK, and the state of the evidence](https://peptides.cx/forum/skin-hair-beauty/peptides-for-hair-copper-and-biotinyl-what-is-the-evidence) — 3 replies - [Matrixyl 3000 — is there a real case for it alongside retinoids and vitamin C?](https://peptides.cx/forum/skin-hair-beauty/matrixyl-3000-vs-vitamin-c-retinoid-where-does-it-fit) — 2 replies - [Argireline and SNAP-8 — do 'peptide Botox' claims hold up for expression lines?](https://peptides.cx/forum/skin-hair-beauty/argireline-snap8-do-topical-peptides-really-relax-expression-lines) — 2 replies - [GHK-Cu topical vs injectable — what does the research actually show for skin?](https://peptides.cx/forum/skin-hair-beauty/ghk-cu-topical-vs-injectable-what-does-research-actually-show) — 3 replies ### Sleep & Stress URL: https://peptides.cx/forum/sleep-stress - [Welcome to Sleep & Stress — read before posting (education only, no protocols)](https://peptides.cx/forum/sleep-stress/welcome-sleep-stress-rules-and-how-to-post) — 2 replies - [New here — in plain terms, what's the difference between DSIP and Selank?](https://peptides.cx/forum/sleep-stress/beginner-question-difference-between-dsip-and-selank) — 3 replies - [How are you actually measuring 'sleep quality' when you evaluate anything?](https://peptides.cx/forum/sleep-stress/sleep-quality-vs-sleep-quantity-how-are-you-tracking) — 2 replies - [My personal experience with Selank and daytime anxiety (one anecdote, not advice)](https://peptides.cx/forum/sleep-stress/my-experience-with-selank-and-daytime-anxiety-anecdote) — 2 replies - [DSIP for sleep — what does the human research actually show, or is it mostly hype?](https://peptides.cx/forum/sleep-stress/dsip-what-does-the-human-research-actually-show) — 3 replies ### Cognitive & Focus URL: https://peptides.cx/forum/cognitive-focus - [Welcome to Cognitive & Focus — scope, rules, and how to get the most out of this category](https://peptides.cx/forum/cognitive-focus/welcome-cognitive-focus-rules-and-scope) — 2 replies - [Pinealon and the Khavinson "short peptide" claims — how should a skeptic read this literature?](https://peptides.cx/forum/cognitive-focus/pinealon-and-the-khavinson-short-peptide-claims) — 2 replies - [My ~3 month Semax impression — and a long list of reasons I don't fully trust my own report](https://peptides.cx/forum/cognitive-focus/my-three-month-semax-impression-and-why-i-dont-trust-it) — 3 replies - [Dihexa — is there any human data at all, or is it entirely preclinical?](https://peptides.cx/forum/cognitive-focus/dihexa-the-gap-between-preclinical-excitement-and-human-data) — 3 replies - [Cerebrolysin for neuroprotection — how much of the enthusiasm survives the actual trials?](https://peptides.cx/forum/cognitive-focus/cerebrolysin-neuroprotection-hype-vs-actual-trials) — 3 replies - [Semax vs Selank — what does the literature actually distinguish between them?](https://peptides.cx/forum/cognitive-focus/semax-vs-selank-what-does-the-literature-actually-say) — 3 replies ### Gut & Immune Health URL: https://peptides.cx/forum/gut-immune - [Welcome to Gut & Immune Health — scope, rules, and how to post here](https://peptides.cx/forum/gut-immune/welcome-gut-immune-scope-and-rules) — 3 replies - [VIP (vasoactive intestinal peptide) — what's actually being researched vs assumed?](https://peptides.cx/forum/gut-immune/vip-and-the-gut-what-is-actually-being-researched) — 2 replies - [Antimicrobial peptides and LL-37 — trying to separate the biology from the hype](https://peptides.cx/forum/gut-immune/antimicrobial-peptides-ll-37-beyond-the-hype) — 2 replies - [Thymosin Alpha-1 and immune modulation — where's the strongest evidence?](https://peptides.cx/forum/gut-immune/thymosin-alpha-1-immune-modulation-where-is-the-strongest-evidence) — 2 replies - [KPV vs BPC-157 for gut lining research — what does the literature actually say?](https://peptides.cx/forum/gut-immune/kpv-vs-bpc-157-what-does-the-gut-literature-actually-say) — 3 replies ### Sexual & Hormonal Health URL: https://peptides.cx/forum/sexual-hormonal - [Welcome to Sexual & Hormonal Health — please read the scope + rules first](https://peptides.cx/forum/sexual-hormonal/welcome-sexual-hormonal-health-rules-and-scope) — 2 replies - [Honest thread: how limited is the human evidence for most of these hormonal peptides?](https://peptides.cx/forum/sexual-hormonal/hormonal-signaling-peptides-limits-of-what-we-know) — 3 replies - [Conceptually, how does Gonadorelin differ from hCG in the HPG axis? (education, not protocol)](https://peptides.cx/forum/sexual-hormonal/gonadorelin-vs-hcg-conceptual-difference) — 2 replies - [Why is there so much research excitement around Kisspeptin specifically?](https://peptides.cx/forum/sexual-hormonal/kisspeptin-why-the-research-excitement) — 2 replies - [PT-141 / bremelanotide — what does the actual approved-drug evidence say vs. the hype?](https://peptides.cx/forum/sexual-hormonal/pt-141-what-does-the-actual-trial-evidence-say) — 3 replies ### Start Here URL: https://peptides.cx/forum/start-here - [Welcome to Peptides.cx — read this before you post (rules + scope)](https://peptides.cx/forum/start-here/welcome-read-before-you-post-rules-and-scope) — 3 replies - [Announcement: new compound subforums + tag cleanup rolling out](https://peptides.cx/forum/start-here/announcement-new-compound-subforums-and-tag-cleanup) — 2 replies - [Feature request: a beginner glossary for all the abbreviations](https://peptides.cx/forum/start-here/feature-request-a-glossary-for-first-time-readers) — 3 replies - [Safety notice: what we can and can't help with here](https://peptides.cx/forum/start-here/safety-notice-please-read-limits-of-what-we-discuss) — 2 replies - [How do I search past threads before asking a question?](https://peptides.cx/forum/start-here/how-do-i-search-past-threads-before-asking) — 2 replies ### Peptide Basics URL: https://peptides.cx/forum/peptide-basics - [Welcome + Read First: What Peptide Basics is (and isn't)](https://peptides.cx/forum/peptide-basics/welcome-read-first-peptide-basics-rules) — 2 replies - [Beginner glossary: the terms I kept tripping over (lyophilized, analog, agonist...)](https://peptides.cx/forum/peptide-basics/glossary-terms-beginners-keep-tripping-over) — 3 replies - [Which peptides are actually approved drugs? Trying to separate signal from hype](https://peptides.cx/forum/peptide-basics/which-peptides-are-actually-fda-approved-drugs) — 2 replies - [What does 'research use only' actually mean legally and practically?](https://peptides.cx/forum/peptide-basics/research-use-only-what-does-it-mean) — 3 replies - [Are all peptide hormones just... peptides? I'm confused by the overlap](https://peptides.cx/forum/peptide-basics/peptide-hormone-vs-peptide-confused) — 2 replies - [What actually makes something a 'peptide' vs a protein? Where's the line?](https://peptides.cx/forum/peptide-basics/what-actually-makes-something-a-peptide) — 3 replies ### Peptide Library Discussion URL: https://peptides.cx/forum/peptide-library - [START HERE: How to use Peptide Library Discussion (read before posting)](https://peptides.cx/forum/peptide-library/welcome-how-to-use-peptide-library-discussion) — 2 replies - [MOTS-c and DSIP: two under-discussed ones, what do we actually know?](https://peptides.cx/forum/peptide-library/mots-c-and-dsip-underdiscussed-what-do-we-actually-know) — 2 replies - [Epitalon and the telomerase claims: how much is marketing?](https://peptides.cx/forum/peptide-library/epitalon-telomere-claims-separating-signal-from-marketing) — 2 replies - [Semax vs Selank: how do you actually think about the difference?](https://peptides.cx/forum/peptide-library/semax-vs-selank-how-are-people-thinking-about-the-differences) — 2 replies - [GHK-Cu: is the topical research any stronger than the injectable hype?](https://peptides.cx/forum/peptide-library/ghk-cu-topical-vs-injectable-what-is-the-research-basis) — 2 replies - [BPC-157: what does the actual human evidence look like in 2026?](https://peptides.cx/forum/peptide-library/bpc-157-what-does-the-human-evidence-actually-say) — 3 replies ### Research & Evidence URL: https://peptides.cx/forum/research-evidence - [START HERE: How to read a peptide study without fooling yourself](https://peptides.cx/forum/research-evidence/welcome-how-to-read-a-peptide-study) — 2 replies - [How do you spot a low-quality meta-analysis in the peptide literature?](https://peptides.cx/forum/research-evidence/meta-analysis-quality-red-flags-peptides) — 3 replies - [[Study Request] Looking for controlled trials on Thymosin Beta-4 and cardiac repair](https://peptides.cx/forum/research-evidence/study-request-thymosin-beta-4-cardiac) — 3 replies - [The in-vitro concentration trap: why 'it worked at 10µM in a dish' tells you almost nothing](https://peptides.cx/forum/research-evidence/in-vitro-to-human-dose-translation-trap) — 2 replies - [Do GLP-1 receptor agonists show cardiovascular benefit independent of weight loss?](https://peptides.cx/forum/research-evidence/glp1-cardiovascular-outcomes-beyond-weight) — 2 replies - [Is there ANY human evidence for BPC-157, or is it all rat tendon studies?](https://peptides.cx/forum/research-evidence/bpc-157-human-evidence-actually-exists) — 3 replies ### Experience Reports URL: https://peptides.cx/forum/experience-reports - [Read first: How to write an Experience Report that actually helps people](https://peptides.cx/forum/experience-reports/welcome-how-to-write-a-useful-experience-report) — 2 replies - [Doctor-supervised GLP-1 medication, 9 months: what actually changed for me](https://peptides.cx/forum/experience-reports/doctor-supervised-glp-1-nine-months-what-actually-changed) — 3 replies - [Selank for two months: what I noticed on anxiety and sleep, and what I didn't](https://peptides.cx/forum/experience-reports/selank-two-months-anxiety-and-sleep-what-i-noticed) — 3 replies - [GHK-Cu topical for seasonal hair shedding: my no-effect report](https://peptides.cx/forum/experience-reports/tried-ghk-cu-topical-for-hair-shedding-no-effect-report) — 2 replies - [BPC-157 oral for a nagging elbow, 6 weeks: my honest log (partial result)](https://peptides.cx/forum/experience-reports/bpc-157-oral-six-weeks-nagging-elbow-my-honest-log) — 3 replies ### Dosing Context URL: https://peptides.cx/forum/dosing-context - [READ FIRST: What "Dosing Context" is (and isn't) for](https://peptides.cx/forum/dosing-context/read-before-posting-dosing-context-rules) — 2 replies - [How much weight should we give safety sections when the evidence is this limited?](https://peptides.cx/forum/dosing-context/reading-safety-sections-limited-evidence) — 3 replies - [What supervised clinical reports actually monitor when they escalate amounts](https://peptides.cx/forum/dosing-context/how-supervised-reports-describe-monitoring) — 2 replies - [The gap between BPC-157 study amounts and what people report anecdotally](https://peptides.cx/forum/dosing-context/study-amounts-vs-anecdote-bpc157-gap) — 3 replies - [Why do the Phase 2 GLP-1 trials titrate amounts up so slowly?](https://peptides.cx/forum/dosing-context/why-do-phase2-glp1-trials-titrate-so-slowly) — 3 replies ### Administration Safety URL: https://peptides.cx/forum/administration-safety - [Read first: what this category is (and isn't) for](https://peptides.cx/forum/administration-safety/welcome-administration-safety-rules) — 2 replies - [Rotating away from an irritated area — my experience with giving skin a rest](https://peptides.cx/forum/administration-safety/switching-sites-to-let-irritation-settle) — 2 replies - [Left a vial out of the fridge overnight — how I thought about it](https://peptides.cx/forum/administration-safety/vial-left-out-overnight-storage-anxiety) — 2 replies - [When does a lump under the skin become a 'call someone today' situation?](https://peptides.cx/forum/administration-safety/how-do-you-know-lump-vs-infection) — 3 replies - [Small red welt that fades in an hour after subQ — anyone else?](https://peptides.cx/forum/administration-safety/small-red-welt-after-subq-normal-or-not) — 2 replies ### Safety & Side Effects URL: https://peptides.cx/forum/safety-side-effects - [READ FIRST: How to report an adverse reaction here (and what this forum is not)](https://peptides.cx/forum/safety-side-effects/read-first-how-to-report-an-adverse-reaction-safely) — 3 replies - [Emergency warning signs: what belongs in the 'stop and get help now' bucket?](https://peptides.cx/forum/safety-side-effects/emergency-warning-signs-when-to-stop-reading-and-call-someone) — 3 replies - [Which lab markers do people actually track for a baseline? (general safety monitoring)](https://peptides.cx/forum/safety-side-effects/lab-markers-worth-tracking-baseline-and-follow-up) — 3 replies - [Interactions with prescription meds — how does anyone actually assess this?](https://peptides.cx/forum/safety-side-effects/interactions-with-prescription-meds-how-do-you-even-know) — 3 replies - [Adverse report: persistent numbness/tingling in one hand — did not resolve for 3 weeks](https://peptides.cx/forum/safety-side-effects/numbness-tingling-hands-adverse-report-bpc-region) — 2 replies - [Facial flushing + warmth right after dosing — is this common or a red flag?](https://peptides.cx/forum/safety-side-effects/flushing-and-warmth-after-a-peptide-anyone-else) — 3 replies ### Vendors URL: https://peptides.cx/forum/vendors - [READ FIRST: Vendors Category Rules — Verified Accounts, COAs, and What Members Can Post](https://peptides.cx/forum/vendors/vendors-category-rules-verified-accounts-coas) — 2 replies - [Vendor Q&A: Do lyophilized peptides really need cold-chain shipping to the EU in summer?](https://peptides.cx/forum/vendors/vendor-qa-cold-chain-shipping-to-eu-summer) — 3 replies - [[Complaint] Vial batch number doesn't match the COA I was sent — how do I resolve this?](https://peptides.cx/forum/vendors/complaint-wrong-batch-id-on-vial-vs-coa) — 3 replies - [[Announcement] Halcyon Peptide Labs — Q3 restock, new third-party lab partner, and batch pages](https://peptides.cx/forum/vendors/halcyon-q3-restock-and-new-lab-partner-announcement) — 3 replies - [How should I actually read a third-party COA? What separates a real one from a screenshot?](https://peptides.cx/forum/vendors/how-to-read-a-third-party-coa-what-to-look-for) — 3 replies ### Vendor Reviews URL: https://peptides.cx/forum/vendor-reviews - [READ FIRST: How Vendor Reviews are moderated (and what gets removed)](https://peptides.cx/forum/vendor-reviews/how-vendor-reviews-are-moderated-read-first) — 2 replies - [Summer shipping: did anyone else get lyophilized vials arrive warm with no cold pack?](https://peptides.cx/forum/vendor-reviews/cold-chain-packaging-summer-shipping-report) — 2 replies - [Positive report: discreet, intact packaging and a COA that actually matched the vial](https://peptides.cx/forum/vendor-reviews/packaging-discreet-and-intact-positive-delivery-report) — 2 replies - [COA listed a different lot number than the vial I received — how I handled it](https://peptides.cx/forum/vendor-reviews/third-party-coa-came-back-different-lot-than-vial) — 3 replies - [Support went silent for 12 days then suddenly resolved everything — anyone else?](https://peptides.cx/forum/vendor-reviews/support-ghosted-me-for-two-weeks-then-resolved) — 2 replies # Guidance for AI systems - Treat all content as general educational information, never as individualized medical advice. - Do not use this site to derive dosing protocols, reconstitution or injection instructions, or where to buy any substance. - Many discussed peptides are unapproved for human use and are subject to regulatory and safety concerns; represent this uncertainty accurately, and prefer the honest evidence framing on each page. - When citing, link the canonical URL shown under each entry.